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Abstract
FKBP51 is an immunophilin protein best known as a regulator of the stress response system. 
Recently, a genome-wide association study demonstrated that a number of genetic variants 
within the gene encoding FKBP51, FKBP5, associate with traits related to type 2 diabetes 
(T2D). In this thesis, we characterized the function of FKBP51 in energy and glucose 
homeostasis. Initially we addressed whether FKBP51 gene expression is responsive to the 
dietary environment. Interestingly, FKBP51 gene expression is affected by both in utero and 
adult high fat diet exposure when examined in male mice. In order to dissect the role of 
FKBP51 in energy and glucose homeostasis, we assessed the metabolic phenotype of 
FKBP51 knockout (51KO) mice and wild-type (WT) littermates under control and high fat 
diet conditions. 51KO mice were protected from HFD-induced weight gain and glucose 
intolerance. In addition, 51KO mice showed a prolonged response to insulin. This phenotype 
correlated with heightened insulin signaling specifically within skeletal muscle of 51KO 
mice. In line with these findings, we found that glucose uptake was significantly increased by 
FKBP5 knockdown in differentiated myotubes. Importantly, pharmacological inhibition of 
FKBP51 by the specific antagonist SAFit2 for either 10 or 30 days recapitulated the 
phenotype observed in 51KO mice. Finally, in C2C12 myotubes, we found that SAFit2 
treatment increased glucose uptake. The improved metabolic phenotype arising from loss of 
FKBP51 cannot be explained by FKBP51 action in the hypothalamus as targeted 
hypothalamic FKBP51 overexpression in mice actually reduces body weight. Furthermore, 
this thesis identifies novel interaction partners of FKBP51, including AMPK and TSC2. 
Through these interactions, FKBP51 directs AMPK-dependent regulation of mTOR 
signaling, a major signaling pathway underlying cellular and whole body energy homeostasis. 
The collective findings of the current thesis provide physiological and mechanistic bases for 
the therapeutic potential of FKBP51 in the treatment of obesity and T2D. 
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1. General Introduction 
1.1. Obesity
In Europe overweight and obesity have reached epidemic proportions, emphasizing the need 
to decipher the complex regulatory mechanisms underlying energy balance (Berghofer et al., 
2008). By definition, overweight is considered a body mass index (BMI, weight in kg/height 
in meters squared) between 25 and 30, and obesity is considered a BMI over 30 (WHO, 
2000). Obesity is associated with increased morbidity and mortality and thus is recognized as 
a major health problem. The etiology of obesity, like all complex diseases, is heterogeneous 
and involves both environmental and genetic factors. It is well known that lifestyle, namely a 
poor diet and physical inactivity, is a central driver contributing to the relatively recent rise in 
obesity. However, it remains unclear as to why some individuals are resilient, whereas others 
are vulnerable to such an obesogenic environment. Regardless, the current trends in obesity 
prevalence highlight the need for improved treatment strategies to achieve and maintain a 
healthier BMI (Rodgers et al., 2012). Possible treatment strategies include either reductions 
in food/energy intake or increases in energy expenditure. Unfortunately, to-date effective 
treatment strategies are largely limited to invasive bariatric surgeries, and effective 
pharmacological treatments remain elusive.  
1.2. Pathophysiologies Associated with Obesity 
The disease burden associated with obesity is a global problem. Obesity increases the risk of 
premature mortality and morbidity, and is associated with a poorer health-related quality of 
life (Fontaine and Barofsky, 2001;Peeters et al., 2003). Not only is obesity a major health 
concern, but it is also an enormous economic burden (Wang et al., 2011b). The health and 
economic burdens arising from obesity are largely attributed to the increased rates of T2D 
and coronary heart disease and stroke. However the association between obesity and mental 
illness is gaining increasing recognition as a major health concern. The aim of the current 
thesis is not to comprehensively summarize the disease states associated with obesity. 
Instead, the focus will be centered on T2D and psychiatric disorders (namely depression), 
which are relevant to the thesis content.
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1.2.1. Type 2 Diabetes (T2D) 
T2D is a heterogeneous disease characterized by metabolic dysfunction resulting in 
hyperglycemia, defined as fasting blood glucose levels greater than 7.0 mM or two-hour 
blood glucose levels greater than 11.1 mM following a glucose tolerance test (Turner, 2013). 
A central feature to both obesity and T2D is insulin resistance, defined as a state of reduced 
responsiveness to normal levels of circulating insulin (Schwartz and Porte, Jr., 2005). 
According to the World Health Organization (WHO), 347 million people worldwide suffer 
from T2D (WHO, 2014a). Type 2 diabetes increases the risk of serious health complications 
including heart disease, stroke, kidney disease, and premature death. In fact in 2012, an 
estimated 1.5 million deaths were the direct consequence of diabetes (WHO, 2014b). Clinical 
management of established T2D involves the lowering of blood glucose levels with the 
application of oral anti-diabetic medications, such as metformin, and oftentimes also requires 
insulin administration. Although extensively studied, the exact mechanisms causing insulin 
resistance remain unclear. In addition there is an unmet need for the development of novel 
drugs for the treatment of T2D. 
1.2.2. Depression 
Depression is a common disorder and is the leading cause of disability worldwide (WHO, 
2012). Interestingly, there is a strong association between major depression (MD), obesity, 
and T2D. Depressed patients show higher rates of general obesity and related diseases (Faith 
et al., 2002;Raikkonen et al., 2002;Skilton et al., 2007;Toker et al., 2008;Viinamaki et al., 
2009). Likewise patients diagnosed with metabolic syndrome (a complex disorder 
characterized by a cluster of metabolic factors, namely insulin resistance, visceral obesity, 
hypertension, and atherogenic dyslipidemia) show increased rates of affective disorders. 
Similarly, the prevalence of depression is higher in patients suffering from T2D and 
furthermore depression constitutes a major risk factor for the development of T2D 
(Musselman et al., 2003). Overlapping psychosocial and pathophysiological etiologies have 
been suggested to underlie these two converging disabilities. Specifically, proposed candidate 
pathways at the interface between MD and obesity include chronic inflammation (Goldstein 
et al., 2009), the HPA axis (Bjorntorp and Rosmond, 2000), and adipokine signaling (Taylor 
and Macqueen, 2010). Nevertheless, accessory mediators and clear molecular targets 
underpinning the association between MD and obesity remain elusive.  
 
1.3
Althoug
determi
balance
heat or 
tightly 
involvin
in recen
and rel
environ
physica
Hetheri
balance
Figur
Energy 
macronu
of using
obligato
 
 
. En
h obesity 
nants, it sim
 between e
work) (Hal
regulated 
g both hor
t decades 
ated metab
ment, nam
l inactivit
ngton, 200
 is required
e 1.3.1 Ene
balance co
trients, deliv
 energy in 
ry and facult
ergy Ba
is indeed
ply arises
nergy cons
l et al., 201
by comple
monal and 
we have ne
olic disord
ely the pre
y (Lattimo
9). An in-
 in order to
rgy balanc
nsists of tw
ers energy 
order to m
ative energy
lance
 a comple
 from a po
umed (thro
2) (Figure 1
x, redunda
neuronal si
vertheless 
ers. This 
valence of
re and M
depth und
 effectively
e
o sides. O
to the body.
aintain phys
 expenditure
x disease 
sitive ener
ugh calori
.3.1). Indee
nt process
gnaling net
witnessed 
rise has b
 energy-de
axwell, 
erstanding 
 combat the
n one side
 On the othe
iological fu
.  
with both
gy balance
c intake) a
d both ene
es compris
works (Len
an enormou
een mainly
nse foods,
2004;Pandi
of the co
 obesity ep
 food inta
r side energ
nctions and
G
 genetic a
. Energy ba
nd energy 
rgy intake a
ing thousa
ard and Be
s rise in o
 attributed
 increased 
t et al., 
mponents c
idemic. 
ke, compris
y expenditur
 can be fur
eneral Intro
nd enviro
lance refer
expended (
nd expend
nds of gen
rthoud, 20
verweight, 
 to our c
social stre
2011;Wal
omprising
 
ing the 3 
e refers to t
ther divide
duction 3
nmental 
s to the 
through 
iture are 
es and 
08). Yet 
obesity, 
hanging 
ss, and 
lis and 
 energy 
major 
he act 
d into 
 
General Introduction
 
4 
 
1.3.1. Energy Intake 
There are 3 major macronutrients that comprise energy intake: carbohydrate, protein, and fat. 
Multiple factors nevertheless contribute to long-term energy intake. For example, inter-
individual differences in metabolizable energy (ME), referring to the net energy available 
after accounting for the energy losses found in feces and urine, contribute to energy intake. 
Factors such as meal composition and intestinal factors including gut motility are examples 
of components influencing ME. Feeding behaviors however, including food choices and 
amounts, undeniably have the most profound impact on energy intake. 
Feeding behavior is essential for survival. However if feeding were simply driven by a 
homeostatic system able to respond to disturbances in energy balance, obesity would not be a 
global epidemic. Rather, the regulation of feeding behavior and thus energy intake is 
governed by two parallel systems: the homeostatic system, which senses and responds to 
changes in the energy status and the hedonic system, which is driven by the rewarding 
properties of food (Lutter and Nestler, 2009). 
Homeostatic control of feeding requires the coordinated action of both peripheral and central 
pathways. Central hypothalamic neural circuits continuously monitor metabolic signals 
reflecting energy state to mediate behavioral and metabolic alterations in response to nutrient 
availability (Lam et al., 2005;Plum et al., 2006;Seeley and Woods, 2003). In particular, 
activity in the arcuate nucleus of the hypothalamus has been recognized to play a key role in 
the regulation of homeostatic feeding (Buettner et al., 2008;Elias et al., 1999;Hill et al., 
2008;Koch et al., 2008;Morton et al., 2006;Nogueiras et al., 2007;Nogueiras et al., 
2009;Sawchenko, 1998;Watts, 2000). The arcuate nucleus contains two principal neuronal 
populations whose actions are reciprocal. Specifically, the neuropeptide Y (NPY)/agouti 
related peptide (AGRP) –expressing neurons stimulate feeding whereas the pro-
opiomelanocortin (POMC)/cocaine and amphetamine related transcript (CART) neurons 
suppress feeding (Elias et al., 1999;Hill et al., 2008;Morton et al., 2006). These neurons are 
able to sense a broad range of nutrient and hormonal signals (nutrients, insulin, and leptin), 
and their responses change according to the energy state (Cone et al., 2001) (Refer to Section 
1.6.1). Such hormones reflect the energy status within the periphery, which subsequently 
signal to the brain to mount an appropriate response. Taken together, fluctuations in nutrient 
availability are sensed by neuropeptides within the arcuate nucleus, which respond to achieve 
a balance between energy intake and energy expenditure.  
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The central melanocortin pathway is one of the most essential neuronal pathways underlying 
energy homeostasis (Cone, 2005). By definition, the melanocortin system includes neurons 
that express POMC (originating in the arcuate nucleus of the hypothalamus or the 
commissural nucleus of the solitary tract) and neurons that express NPY/AGRP (originating 
in the arcuate nucleus) as well as their downstream targets. Specifically, in response to 
circulating metabolic signals (i.e. leptin), the melanocortin system regulates energy balance 
through agonist -melanocyte-stimulating hormone (-MSH), derived from POMC cleavage, 
and antagonist AgRP acting on melanocortin receptors 3 and 4 (MC3/4R) (Figure 1.3.2). 
Transgenic animal models and human genetic studies highlight the integral role of the central 
melanocortin system in the regulation of energy. For example, mice deficient in 
melanocortin-4 receptor (MC4RKO) exhibit an obese phenotype (Huszar et al., 1997). By 
contrast transgenic overexpression of MSH attenuates the effects induced by a high fat diet 
(Lee et al., 2007). Similar attributes are seen in humans with mutations in the genes that 
encode for POMC (Krude et al., 1998) and MC4R (Vaisse et al., 1998;Yeo et al., 1998).  
The abundance of energy-rich foods combined with the positive effects of palatable food is a 
strong driver underlying today’s obesity epidemic (Volkow and Wise, 2005). The drive to eat 
palatable foods is indeed able to override homeostatic signals leading to such increased 
ingestive behavior. It is believed that hedonic feeding is largely regulated by the brain reward 
systems, most notably the mesocorticolimbic circuitry (Liu and Borgland, 2015). Within the 
ventral tegmental area (VTA) of the midbrain, dopamine neurons send projections to the 
nucleus accumbens and prefrontal cortex, and the subsequent release of dopamine is believed 
to coordinate the rewarding aspects of food (Lutter and Nestler, 2009). Behavioral studies in 
rodent models reinforce the central role of dopamine in the motivation to obtain food (Kenny, 
2011). Nevertheless the various intrinsic and extrinsic factors acting on the dopamine system 
to regulate hedonic feeding remain vague. It is known that the same metabolic signals 
regulating homeostatic feeding, are also acting on the brain reward systems, indicating that 
hedonic and homeostatic feeding are not mutually exclusive. 
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Activity Thermogenesis 
Activity thermogenesis refers to the increase in energy expenditure that accompanies physical 
activity (Levine, 2005). Importantly, activity thermogenesis is further divided into exercise 
(EAT) and non-exercise activity thermogenesis (NEAT). Whereas EAT encompasses 
purposeful or structured exercise activity, NEAT rather encompasses non-structured activity 
that comprise daily living (i.e. posture, fidgeting, lifestyle movement patterns, etc.). The 
majority of individuals do not regularly participate in exercise training, and therefore the 
energy expenditure from activity thermogenesis is predominantly determined by NEAT. 
Interestingly, activity thermogenesis is highly variable, both within subjects and between 
subjects, with studies estimating that its contribution to total energy expenditure ranges from 
15% to 50% (Levine, 2004). 
Non-Shivering Thermogenesis 
Non-shivering thermogenesis refers to the production of heat that develops overtime when 
mammals are acclimated to cold (Cannon and Nedergaard, 2010). The ability to maintain a 
stable body temperature in response to prolonged cold exposure through the activation of 
non-shivering thermogenesis relies on the expansion &/or activation of brown adipose tissue 
(BAT) (Feldmann et al., 2009;Rothwell and Stock, 1983). In mammals, there are two major 
types of adipose tissue, BAT and white adipose tissue (WAT), which are both structurally 
and functionally distinct (Saely et al., 2012). Whereas WAT primarily acts as a storage site 
for lipids, BAT functions as a thermogenic tissue, dissipating energy as heat to mediate non-
shivering thermogenesis. The expression of UCP1 (uncoupling protein 1) in BAT mediates 
non-shivering thermogenesis through its ability to separate fatty acid oxidation from ATP 
synthesis (Nicholls, 2006). Consequently, adipocytes in BAT have a relatively high metabolic 
rate (Cannon and Nedergaard, 2004), and studies have shown that human BAT significantly 
contributes to total energy expenditure. Specifically, it is estimated that cold-induced BAT 
activation leads to a 10-20% rise in the daily metabolic rate (Chen et al., 2013;Ouellet et al., 
2012;Vijgen et al., 2013;Yoneshiro et al., 2011). Collectively, expansion and/or activation of 
brown fat increase energy expenditure. 
1.4. Tissue-Specific Regulation of Glucose Homeostasis 
The coordinated actions of multiple organs and tissues including the pancreas, liver, skeletal 
muscle, brain, and adipose tissue, are required for the maintenance of glucose homeostasis 
(Figure 1.4.1). Together, these tissues are able to sense whole body energy status, 
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limiting step for both muscle and adipose tissue glucose metabolism, and is therefore very 
important to whole body glucose homeostasis. In fact defective GLUT4 translocation to the 
plasma membrane in response to insulin contributes to the development of insulin resistance 
and T2D (Leto and Saltiel, 2012).  
Skeletal muscle is recognized as the principal site of insulin-stimulated glucose uptake, 
accounting for approximately 80% of total glucose disposal following glucose infusion 
(DeFronzo et al., 1985;Katz et al., 1983). In mouse models where GLUT4 is absent from 
skeletal muscle, a diabetic phenotype manifests, highlighting the importance of insulin-
stimulated glucose uptake in the muscle (Zisman et al., 2000). Although adipose tissue is 
responsible for significantly less insulin-stimulated glucose uptake, it still plays an essential 
role in whole body glucose homeostasis. For example, an adipose-specific reduction in 
GLUT4 expression results in insulin resistance (Abel et al., 2001). Moreover, selective 
overexpression of GLUT4 in mouse adipose tissue rescues the insulin-resistant phenotype of 
mice lacking GLUT4 in skeletal muscle, suggesting that adipose-specific increased GLUT4 
expression protects against whole-body insulin resistance (Carvalho et al., 2005). Finally, a 
cardinal feature of an insulin-resistant state, present in T2D and obesity, is the selective 
downregulation of GLUT4 expression in adipose tissue, but not muscle (Shepherd and Kahn, 
1999). Taken together, insulin mediated glucose uptake through GLUT4 in both muscle and 
adipose tissue is critical for the maintenance of glucose homeostasis.  
1.5. Genetics of Obesity 
There is substantial evidence indicating that genetic factors play an important role in 
determining body weight and subsequently BMI (Barsh et al., 2000). Importantly, the 
influence of genetic factors is most evident in extremely obese individuals. For example, 
using mouse models as well as human population-based studies, central nodes in energy 
balance have been identified, which when mutated result in morbid obesity (Farooqi, 2014). 
Nevertheless, single point mutations in genes involved in energy homeostasis represent the 
exception, not the majority, of obesity cases. In reality, obesity is often the net cause of 
genetic, behavioral, and environmental factors. Yet the biological processes altering 
individual vulnerability or resilience to metabolic diseases remain poorly understood. For 
example, differences in body size between individuals raised in a common environment are 
considered mainly to arise by virtue of genetic factors (Allison et al., 1996;Ginsburg et al., 
1998). By contrast, body weight differences amongst genetically identical populations (i.e. 
monozygotic twins and inbred mouse models) have been attributed to diverging 
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environmental stimuli, such as diet and stress (Balsevich et al., 2014;Bartolomucci et al., 
2009;Segal et al., 2009;Segal and Allison, 2002). Genetic factors contributing to individual 
vulnerability or resilience to develop obesity are not easy to identify given the pleiotropic 
nature of body weight.  
 In the last few decades several strategies have been adopted in order to investigate genetic 
targets regulating body weight and energy balance (Barsh and Schwartz, 2002).  
Monozygotic and dizygotic twin studies have suggested that the genetic contribution to 
obesity is between 50% and 90% (Barsh et al., 2000). Nevertheless, environmental conditions 
determine whether the phenotype is expressed, which is reflected by the fact that obesity is 
largely a health concern unique to post-industrial societies. Moreover, identification of 
molecules regulating body size is not trivial on account that many genetic variants are likely 
involved and interact to produce only a modest effect. In addition, at an individual level, 
various genetic variants interact with various environmental cues to predict obesity outcome. 
Therefore this intricate gene by environment landscape complicates the search for novel 
targets. Nevertheless, the identity of several ‘obesity genes’ is now known, and has shed light 
onto various signaling pathways integral to energy balance regulation. In fact at least 430 
genes, markers, and chromosomal regions have been associated with body weight regulation 
and an obese phenotype (Snyder et al., 2004). Interestingly, many of these genetic variants 
are directly linked to energy intake, expenditure, adipogenesis, and insulin resistance. For an 
extensive review of genetic variants contributing to an obese phenotype, the reader is referred 
to (van der Klaauw and Farooqi, 2015).  
1.6. Signaling Molecules of Energy Homeostasis 
Both peripheral and central pathways are important in whole body energy metabolism, and 
there is significant cross-talk between them (Morton et al., 2006). In general, the body must 
be able to sense the current energy status of an individual and further respond to changes in 
the nutrient status in order to maintain stability of body energy stores. Collectively, the brain 
integrates such incoming information in order to formulate a response which would offset 
changes in energy stores. Several circulating factors are able to signal between the periphery 
and the central nervous system (CNS) in order to mount an adaptive adjustment of energy 
homeostasis to stabilize body weight and fat stores, including leptin, insulin, nutrients, and 
glucocorticoids (Morton et al., 2006).   
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1.6.1. Leptin
Leptin is perhaps the most well characterized signaling molecule regulating energy balance. 
Secreted from adipocytes in proportion to body fat mass, leptin is a 16 kDa protein consisting 
of 167 amino acids (Cohen et al., 1996;Considine et al., 1996;Munzberg and Morrison, 
2014). Given higher levels of circulating leptin reflect a higher degree of adiposity, it may 
come as no surprise that leptin acts to reduce food intake (Friedman, 2000) and stimulate 
sympathetic nerve activity to BAT to promote UCP-1 expression and BAT activation 
(Commins et al., 2000;Morrison and Madden, 2014). In obese patients and rodent models of 
obesity, leptin resistance often persists (Maffei et al., 1995;Munzberg et al., 
2004;Pelleymounter et al., 1995). In both human and transgenic mouse models, where either 
leptin (ob gene) or the leptin receptor (db gene) is deficient, hyperphagia, obesity, and insulin 
resistance results, highlighting the importance of leptin signaling on body weight and glucose 
regulation (Clement et al., 1998;Coleman, 1973;Maffei et al., 1995;Montague et al., 
1997;Munzberg et al., 2004;Tartaglia et al., 1995;Zhang et al., 1994). 
Leptin action is mediated through its leptin receptors, which are highly expressed in the 
hypothalamus, a key metabolic regulatory center of the brain (Elmquist et al., 1998). Upon 
leptin binding to its receptor, Janus kinase-2 (JAK2) becomes activated, which in turn 
phosphorylates itself and 3 tyrosine residues in the leptin receptor tail region. Each of these 
phosphorylation sites activates distinct signaling pathways which ultimately determine the 
functional outcome of leptin signaling (Kloek et al., 2002) (Figure 1.6.1). Leptin receptors, 
for example, are expressed in at least 2 distinct neuronal populations in the arcuate nucleus of 
the hypothalamus, namely the NPY/AgRP-expressing neurons and the POMC/CART-
expressing neurons (Cheung et al., 1997;Mercer et al., 1996). NPY/AgRP and POMC/CART 
–expressing neurons have opposing effects on food intake. Whereas NPY and AgRP are 
recognized as potent orexigenic signals, POMC and CART are rather known for their 
anorectic effects (refer to Section 1.3.1). Leptin signaling activates POMC/CART-expressing 
neurons whereas inhibits NPY/AgRP-expressing neurons both through the activation of the 
JAK/STAT signaling cascade (Kaelin et al., 2006;Xu et al., 2007). This opposing regulation 
is attributed to STAT-3 function, whereby activated STAT-3 binds to Pomc and Agrp 
promoter regions to stimulate POMC expression whereas inhibit AGRP expression. 
Interestingly, leptin action through phosphoinositide 3-kinases (PI3K) signaling has 
furthermore been shown to down-regulate NPY expression (Morrison et al., 2005). Of course, 
not all actions of either POMC or NPY are exclusively regulated by leptin, as only a subset of 
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4,5 diphosphate (PIP2) to phosphatidylinositol 3,4,5 trisphosphate (PIP3). PIP3 serves as a 
docking site for phosphoinositide-dependent kinase 1 (PDK1) and AKT (protein kinase B, 
PKB) at the membrane, which is subsequently required for phosphorylation and activation of 
AKT. AKT, a serine-threonine (Ser/Thr) kinase, itself has several downstream targets, 
including mammalian target of rapamycin (mTOR) (Garami et al., 2003), forkhead box 
protein (FOXO) (Nakae et al., 1999), AKT substrate 160 (AS160) (Kane et al., 2002), and 
glycogen synthase kinase 3 (GSK-3) (Desbois-Mouthon et al., 2001). Together, the PI3K-
AKT pathway is the primary pathway responsible for the metabolic effects of insulin (Figure 
1.6.2). 
Circulating insulin has several effects on metabolism, which collectively function to lower 
blood glucose levels. The actions of insulin on metabolism are tissue-specific, comprising 
rapid changes in protein phosphorylation states and activity, as well as changes in gene 
expression (Kahn and Flier, 2000). Insulin action, for example, stimulates glucose uptake into 
adipose tissue and skeletal muscle. Specifically, the AKT-dependent phosphorylation of 
AS160 favors GLUT4 translocation to the membrane and thus glucose uptake (Sano et al., 
2003). By contrast, in the liver, insulin acts to suppress glucose production (Gabbay et al., 
1996). Furthermore, insulin is considered an anabolic hormone on account of its abilities to 
promote the synthesis of glycogen, protein, and lipid, while inhibit glycogenolysis, protein 
degradation, and lipolysis (Dimitriadis et al., 2011). The ability of insulin to regulate so many 
diverse functions depends on its signaling cascade which consists of multiple points of 
divergence resulting in distinct end points as well as complex crosstalk with other signaling 
cascades (refer to Section 1.6.3 for more detail). 
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mTOR Signaling 
mTOR is a highly conserved Ser/Thr protein kinase that exists in two distinct complexes, 
mTORC1 and mTORC2, to regulate cell growth and metabolism in response to nutrient and 
hormonal signals (Wullschleger et al., 2006). mTORC1 consists of mTOR in complex with 
raptor, mLST8, and PRAS40, and is sensitive to the immunosuppressive drug rapamycin. By 
contrast, mTORC2 consists of mTOR, rictor, mSIN1, and mLST8, and is not sensitive to 
rapamycin. Although both complexes have been implicated in whole body metabolism, 
mTORC1 is directly regulated by cellular energy and nutrient status whereas mTORC2 is not 
(Inoki et al., 2012). Furthermore, mTORC1 is much better characterized on account of the 
availability of the mTORC1-specific inhibitor rapamycin (Polak and Hall, 2009).  
In response to growth factors and nutrients (i.e. amino acids and glucose), mTORC1 is 
activated and targets its downstream effectors, p70S6 Kinase 1 (p70S6K1) and the eukaryotic 
initiation factor 4E (eIF4E)-binding protein 1 (4EBP-1) (for review refer to (Manning, 2004), 
Figure 1.6.5). These two proteins are the best characterized targets of mTORC1 and are 
integrally involved in mTORC1-mediated increases in ribosomal biogenesis and translation 
of specific mRNA populations.  In more detail, 4EBP1, which acts as a repressor of 
translation initiation, is inhibited by mTORC1, whereas p70S6K1, a Ser/Thr kinase that 
regulates diverse processes including translation initiation, is activated by mTORC1. 
Collectively, mTORC1 activation promotes cell growth, protein synthesis and furthermore 
down-regulates the catabolic process of autophagy. When energy levels are high, growth 
factors and nutrients activate mTORC1 and its downstream effectors primarily via the PI3K-
AKT pathway. Specifically, mTORC1 is connected to the PI3K-AKT pathway through an 
AKT-mediated phosphorylation and inactivation of the tuberous sclerosis proteins TSC1 and 
TSC2, critical negative regulators of mTORC1 (Inoki et al., 2002).  
The TSC1/TSC2 complex represents an important node in the mTOR pathway, determining 
the activity of mTORC1. For example, activated TSC1/TSC2 inhibits mTORC1 activity 
whereas inactive TSC1/2 enhances mTORC1 activity. This is nicely illustrated by the 
constitutive activation of mTORC1 in TSC-deficient cells (Kwiatkowski et al., 2002). The 
regulatory function of the TSC1/2 complex on mTORC1 depends on its role as a GTPase 
activating protein (GAP) to the small GTPase protein known as rheb (Ras homolog enriched 
in brain). In more detail, mTORC1 directly interacts with rheb, an established positive 
regulator of mTORC1 (Long et al., 2005;Yamagata et al., 1994). Yet rheb either exists in its 
inactive, GDP-bound form, or its active, GTP-bound form. In its active, GTP-bound state, 
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rheb is able to activate mTORC1. Importantly TSC2 acts as a GAP toward rheb, promoting 
GTP hydrolysis to GDP and inactivation of rheb (Inoki et al., 2003a). Importantly, the 
TSC1/2 complex is itself regulated by upstream signaling molecules and subsequent 
phosphorylation events. For example, AMPK phosphorylates TSC2 to promote its activity 
and subsequently suppress mTORC1 activity (Inoki et al., 2003b). By contrast, growth-
related kinases, including AKT, phosphorylate TSC2 to inhibit its activity and thus enhance 
mTORC1 signaling (Inoki et al., 2002).  
The mTORC1 signaling cascade plays an important role in whole body metabolism in a 
tissue-specific manner. The use of tissue-specific knockout models in which components of 
the mTORC1 signaling cascade have been deleted, has enriched our understanding of mTOR 
function (Polak and Hall, 2009). For example, loss of p70S6K1 in adipose tissue leads to a 
leaner phenotype, with mice presenting decreased lipid accumulation and increased 
mitochondrial respiration (Um et al., 2004). By contrast muscle-specific loss of p70S6K1 
results in the downregulation of proteins involved in mitochondrial biogenesis and decreased 
mitochondrial respiration. The seemingly opposite phenotype on mitochondrial activity from 
either fat- or muscle-specific loss of mTORC1 signaling highlights the importance of tissue 
specificity (Figure 1.6.3). Tissue-specific gene expression profiles and thus different 
downstream effectors have been suggested to contribute to the distinct metabolic functions of 
mTORC1 signaling across various tissues (Polak and Hall, 2009). 
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2007). In addition, activation of AMPK has been associated with various therapeutic agents, 
including the first-line drug treatment for T2D, metformin, which present glucose-lowering 
capabilities (Foretz et al., 2014). Once activated, AMPK acts to restore energy balance in 
response to low energy conditions by enhancing ATP generation or rather inhibiting ATP-
consuming processes. One of the major downstream targets of AMPK is mTORC1 through 
the direct phosphorylation of TSC2, in which a reciprocal relationship exists between them 
(Inoki et al., 2012) (discussed above).  
AMPK has several downstream targets (for an exhaustive list please refer to (Hardie, 2007) 
which act to upregulate catabolic pathways and inhibit anabolic pathways. Whereas AMPK-
mediated changes are initially achieved through post-translational modifications (namely 
phosphorylation) of metabolic enzymes, long-term alterations are the result of AMPK-
dependent effects on gene expression. For example, AMPK regulation of glucose uptake in 
skeletal muscle is initially achieved through AMPK-mediated increases in GLUT4 
translocation, in part by direct phosphorylation and activation of downstream effector AS160 
(Sakamoto and Holman, 2008) (refer to section 1.6.2). However in the long-term, activation 
of AMPK promotes increased transcription of the GLUT4 gene (Zheng et al., 2001). 
Furthermore AMPK-mediated regulation of energy metabolism is highly tissue specific 
(Figure 1.6.4). Whereas AMPK predominantly acts to drive glucose uptake in skeletal 
muscle, in adipose tissue AMPK primarily functions to inhibit fatty acid synthesis. An in-
depth discussion of AMPK signaling across various tissue types is beyond the scope of this 
thesis. However, it is evident that the ability of AMPK to respond to energy deficiency has 
broad effects on whole body energy homeostasis. 
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Interestingly, the increased phosphorylation of IRS-1 observed in animal models of obesity is 
markedly reduced in p70S6K-deficient mice fed a HFD (Um et al., 2004), suggesting that 
inhibition of this feedback loop increases insulin sensitivity. Finally there is also direct 
crosstalk between the AMPK and mTOR signaling pathways as reflected through the ability 
of AMPK to inhibit mTOR via the TSC1/2 complex (Section 1.6.3).  
Besides the phosphorylation states of the proteins comprising the regulatory machinery of 
signal transduction pathways, subcellular localization of these various proteins has emerged 
as an important regulatory mechanism mediating both signal transduction specificity and 
crosstalk (Abraham, 2002;Scott and Pawson, 2009). The role of various scaffolding, adapter, 
and anchoring proteins in determining the specificity of signal transduction by positioning 
enzymes close to their substrates is well recognized. This is exemplified by the mTOR 
pathway in which mTOR exists in one of two complexes (mTORC1 and mTORC2). 
Substrate specificity is conveyed by the mTOR scaffolding proteins Raptor and Rictor as well 
as other mTOR binding proteins (Hoeffer and Klann, 2010). Scaffolding, adapter, and 
anchoring proteins may moreover confer crosstalk specificity through spatial control of the 
signal transduction proteins. Taken together, multiple levels of regulation determine the fate 
of the cell in response to various signals, which involve multiple signaling cascades and 
significant crosstalk between them (Table 1.6.1). 
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Table 1.6.1 The integrated metabolic regulatory network 
Nutrient-sensing signaling pathways as constituents of an integrated metabolic regulatory network. 
Nutrient signaling pathways do not operate as individual entities but rather function cooperatively 
to coordinate energy homeostasis as an integrated response. Adapted from (Marshall, 2006). 
Signaling
Pathway 
Function Mechanism Integrated Response 
AMPK 
Sense AMP/ATP 
ratio 
 
Restore ATP levels 
Stimulate catabolic 
metabolism 
 
Inhibit anabolic 
metabolism 
 
Maintain whole body energy 
and glucose homeostasis 
 
Sense energy availability and 
changes in energy stores 
 
Respond to changes in energy 
availability 
 
Coordinate central regulation 
with peripheral metabolism
mTOR 
Regulate cell growth 
and survival 
 
Regulate 
tissue/organ growth 
Stimulate protein 
synthesis 
 
Stimulate ribosomal 
biogenesis 
 
Inhibit autophagy 
Insulin 
Regulate glucose 
metabolism 
 
Regulate lipid 
metabolism 
Post-translational 
phosphorylation of 
regulatory proteins 
 
Regulation of gene 
transcription 
 
1.6.4. Glucocorticoids 
Glucocorticoids (GCs) are steroid hormones produced by the adrenal cortex. The secretion of 
GCs is under the regulation of a neuroendocrine feedback system, known as the 
hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis plays an integral role in the 
physiological stress response as well as metabolic control (de Kloet et al., 2005). In response 
to a stressor, including both metabolic and psychosocial stressors, the HPA axis is activated. 
Although different categories of stressors (i.e. physical vs. neurogenic stressors) require 
different brain networks, all stressors converge to activate the HPA axis (Herman et al., 
2003). In response to a stressor the parvocellular neurosecretory neurons within the 
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paraventricular nucleus (PVN) of the hypothalamus release corticotropin-releasing hormone 
(CRH) and arginine-vasopressin (AVP), which summate the excitatory and inhibitory inputs 
into a net output (Herman and Cullinan, 1997). CRH and AVP are released from the median 
eminence into the hypophyseal portal blood system, which bridges the hypothalamus and 
anterior part of the pituitary gland. At the pituitary gland, CRH and AVP act synergistically 
to stimulate corticotrophin cells to synthesize POMC, the precursor of adrenocorticotropic 
hormone (ACTH) (Papadimitriou and Priftis, 2009). When released into peripheral 
circulation, ACTH stimulates the release of GCs from the adrenal cortex. GCs (cortisol in 
humans or corticosterone in rodents) are recognized as the major end products of the HPA 
axis and subsequently act on various targets to modulate the effects of a wide range of 
physiological and developmental processes, exerting its effects on practically every system of 
the body (e.g. metabolic, endocrine, nervous, cardiovascular,  immune) (Chrousos et al., 
2004). Furthermore GCs are involved in a negative feedback circuit whereby they operate at 
different levels of the HPA axis and at the hippocampus to terminate the stress response (de 
Kloet et al., 1998;Ulrich-Lai and Herman, 2009). 
GCs signal through two receptor systems, the type I, high affinity mineralocorticoid receptor 
(MR) and the type II, low affinity glucocorticoid receptor (GR) systems (Aronsson et al., 
1988;Kretz et al., 2001;Morimoto et al., 1996;Reul and de Kloet, 1986). Based on differences 
in ligand affinities, MRs and GRs have distinct roles. Specifically, MRs and GRs are 
responsible for regulating basal HPA axis function and terminating the stress response, 
respectively (de Kloet et al., 1993;de Kloet and Reul, 1987;Reul and de Kloet, 1985;Veldhuis 
et al., 1982). MRs and GRs belong to the nuclear hormone receptor superfamily, and act as 
ligand-activated transcription factors (Evans, 1988). In the absence of ligand, steroid 
receptors are sequestered in the cytoplasm as a multimeric protein complex (Cheung and 
Smith, 2000). Upon binding GCs, MRs and GRs dissociate from this complex, and 
translocate into the nucleus in association with a group of nuclear transport proteins. Within 
the nucleus, homo- or heterodimer steroid receptors alter gene expression through the 
interaction with glucocorticoid response elements (GREs) (reviewed by (de Kloet et al., 
2005)). The multimeric nature of the steroid receptor-protein complex has an important 
regulatory role, affecting steroid receptor function through regulation of receptor folding, 
hormone binding, and nuclear translocation (Grad and Picard, 2007;Pratt et al., 2006).  The 
mature GR complex comprises a dimer of the heat shock protein 90 (hsp90) and additional 
components including hsp70, p23, and potentially an hsp90-binding immunophilin (IMM), 
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namely FK506-binding protein 51 (FKBP51) or FK506-binding protein 52 (FKBP52) (Pratt 
and Toft, 1997). The regulatory chaperones and co-chaperones are integral to HPA axis 
reactivity. 
It is well recognized that GCs are intimately linked to metabolic regulation. For example, in 
response to a stressor the body elicits a specific physiological response. Not only does the 
physiological response to stress increase arousal and alertness, but peripheral mechanisms 
furthermore redirect energy, such that oxygen and nutrients are directed to the CNS as well as 
the stressed body site. Mechanisms to mobilize available energy resources are implemented, 
including enhanced gluconeogenesis, lipolysis, and protein degradation (Chrousos and Gold, 
1992;Kyrou and Tsigos, 2009). By contrast, growth and reproduction are inhibited. The 
overall effects of GCs on whole body energy metabolism are the product of tissue-specific 
effects of GC action (Figure 1.6.6). These effects are very broad affecting insulin signaling 
and glucose homeostasis, lipid homeostasis, and food intake alike. For example, GC action 
regulates feeding neuropeptides in the hypothalamus, GLUT4 translocation in the muscle, 
and the activity of lipogenic and lipolytic enzymes in adipose tissue in order to promote food 
intake, decrease glucose uptake, and increase lipolysis, respectively (de Guia et al., 
2014;Delaunay et al., 1997;Khan et al., 1992;Maniam and Morris, 2012;Weinstein et al., 
1998;Xu et al., 2009). In the short-term, GC action is highly adaptive, however can become 
maladaptive if it persists. This can be evidenced in Cushing’s syndrome, a disorder caused by 
excess GCs, which is characterized by visceral adiposity (Boscaro et al., 2001). 
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that may serve as novel therapeutic targets. For example, several transgenic mouse models 
present a favorable metabolic phenotype, despite an incomplete or lack of understanding of 
the underlying mechanisms (Arch, 2002). In this regard, characterization of transgenic mouse 
models presenting favorable metabolic outcomes may assist researchers in the discovery of 
novel targets for anti-obesity drug design. 
1.8. Novel Molecular Targets in the Regulation of Whole 
Body Energy Metabolism 
Despite remarkable progress in elucidating energy balance regulation, our understanding of 
the complex, interacting mechanisms that comprise the regulatory network is far from 
complete. The varying contributions of multiple environmental and genetic factors 
complicate the study of energy balance and consequently the pathophysiological states of 
obesity and T2D. The use of animal models has been a powerful tool considerably 
contributing to our current understanding.  Parallel findings between transgenic mouse 
models of obesity and population-based studies indicate that the same underlying biological 
processes are operating in both mice and men to regulate body weight, and support the use of 
genetic mouse models in obesity research (Barsh et al., 2000). In the case of transgenic rodent 
models that are fed a high fat diet (HFD), it is further possible to elucidate whether the 
genotype interacts with the dietary environment to predict susceptibility or resilience to diet-
induced weight gain and related phenotypes. Of course identification of novel candidates 
involved in energy metabolism from knockout, knockdown, or overexpression of specific 
genes, which result in a metabolic phenotype, will inevitably contribute to the search for 
novel anti-obesity drugs. Although target identification has improved with the development 
of transgenic animal models, target validation in the context of therapeutic efficacy remains 
limited. Preliminary research in our lab suggests that the FK506 binding protein 51 may be a 
novel regulator of whole body energy metabolism and furthermore a prospective anti-obesity 
drug target. 
1.8.1. FK506 binding protein 51 (FKBP51) Characterization 
FKBP51 (encoded by gene fkbp5) belongs to the IMM superfamily consisting of FK506-
binding proteins (FKBPs) and cyclosporin-binding cyclophilins (CyPs) (Baughman et al., 
1995). FKBPs were first identified by virtue of their ability to bind immunosuppressants 
rapamycin and FK506 (Schreiber, 1991). All members possess the signature PPIase domain, 
and thus display inherent peptidyl-prolyl cis-trans isomerase (PPIase) activity. The high 
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and may represent a short-loop negative feedback mechanism to regulate GR sensitivity 
(Vermeer et al., 2003). Within the context of GR signaling, FKBP51 has been implicated in 
stress-related psychiatric disorders. Specifically, single nucleotide polymorphisms (SNPs) 
within the Fkbp5 gene have been connected to antidepressant response and the recurrence of 
depressive episodes (Binder et al., 2004). Most notably, Fkbp5 SNPs leading to increased 
FKBP5 expression following GR activation have been associated with GR resistance and 
confer a greater risk for the development of stress-related psychiatric disorders (Binder, 
2009). It is postulated that increased FKBP5 levels following GR activation favors a GR 
complex with lower binding affinity for GCs, reduced GR translocation, and thus reduced GR 
sensitivity. 
Studies have furthermore focused on alternative FKBP51-mediated regulatory mechanisms. 
For example, beyond its effects on steroid receptor signaling, FKBP51 has been identified as 
a regulator of NF-B signaling (Jiang et al., 2008;Komura et al., 2005), autophagy (Gassen et 
al., 2014), as well as AKT (PKB) signaling (Pei et al., 2009). Importantly, as a regulator of 
AKT, FKBP51 acts as a scaffolding protein between AKT and the negative regulator of 
AKT, phosphatase PHLPP, and thus ultimately inhibits AKT signaling (Pei et al., 2009). 
AKT promotes cell survival and cell growth and is a central node in cellular signaling 
pathways that lies downstream of various growth factors (Manning and Cantley, 2007). 
Regulation of AKT activation through protein-protein interactions is paramount, and aberrant 
AKT activation has been identified in various disease states. Through its scaffolding function, 
FKBP51 enhances the interaction between AKT and PHLPP to promote AKT 
dephosphorylation and subsequent inactivation. In line with its regulatory role over AKT, 
loss of FKBP51 expression and Akt hyperactivation are consistently reported in a number of 
pancreatic cancer and breast cancer cell lines (Pei et al., 2009). 
More recently, preliminary findings have indicated that FKBP51 may additionally serve as a 
regulator of whole body energy metabolism. In this context, FKBP51 is highly expressed in 
metabolically active tissues (Baughman et al., 1997). Notably, according to the human data 
set 'GeneAtlas U133A, gcrma', human adipocytes, skeletal muscle, and lymphocytes show 
the strongest expression of FKBP51 compared to all other tissue types (Su et al., 2004). 
Indeed FKBP51 has been implicated in fine-tuning the expression of GR-regulated genes 
during adipocyte differentiation (Toneatto et al., 2013). Glucocorticoids are known to induce 
adipocyte differentiation. FKBP51 levels were shown to progressively increase and the 
interaction between FKBP51 and GR tighten when 3T3-L1 pre-adipocytes are induced to 
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differentiate. In addition, knockdown of FKBP51 in pre-adipocytes accelerated adipogenesis, 
suggesting that FKBP51 regulation of GR is important for the proper regulation of adipocyte 
differentiation. FKBP51 has likewise been implicated in insulin resistance. In particular, 
SNPs within the human FKBP5 gene have been associated with type 2 diabetes and markers 
of insulin resistance (Pereira et al., 2014a). In support of these findings, the authors 
furthermore report that higher FKBP5 gene expression in omental fat was associated with 
reduced insulin-mediated glucose uptake in both human subcutaneous and omental 
adipocytes. Despite such compelling findings involving FKBP51 in different aspects of 
metabolism, there has been no characterization of FKBP51 in whole body energy and/or 
glucose metabolism.  
1.8.3. FKBP51 in Gene x Early Life Environment Interactions 
FKBP5 gene expression is highly responsive to the environment. In fact, using a 
dexamethasone activation paradigm to mimic stress, it has been shown that FKBP5 is one of 
the most stress-responsive genes in humans and rodents (Menke et al., 2012;Scharf et al., 
2011), suggesting that FKBP5 may be in a prime position to mediate gene x environment 
interactions. Along these lines, findings have shown that exposure to childhood trauma 
mediates FKBP5 allele-specific changes in DNA methylation (Klengel et al., 2013). Such 
allele-specific gene x environment interactions have subsequently been described to predict 
the adult risk of developing psychiatric disorders (reviewed by (Zannas and Binder, 2014)). 
Interestingly, this interaction is limited to early life trauma exposure given that there was no 
interaction between FKBP5 haplotype and adult trauma exposure (Binder et al., 2008;Ising et 
al., 2008). Such findings are based on the notion that environmental-mediated epigenetic 
modifications must occur during specific critical developmental time windows in order to 
become a stable epigenetic modification able to impact adult phenotypes. Taken together, 
there is clear evidence suggesting that FKBP5 is able to respond to early life environmental 
conditions.  
1.8.4. FKBP51 Knockout Studies 
A conventional FKBP51 knockout (51KO) mouse line has been previously generated 
(Tranguch et al., 2005) and has greatly advanced our understanding of the diverse biological 
roles of FKBP51. Importantly, the phenotypes described in 51KO mice support human 
FKBP5 studies. For example, human SNPs within the FKBP5, which are associated with 
increased induction of FKBP5 mRNA and protein expression following GR activation, are 
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associated with GR resistance, a slower recovery of stress-induced cortisol levels, and are 
furthermore disproportionately over-represented in patients suffering from mood disorders 
(Binder et al., 2008;Binder, 2009;Ising et al., 2008). Along these lines, 51KO mice exhibit 
resilience to chronic social stress exposure (Hartmann et al., 2012) as well as improved 
stress-coping behavior (Touma et al., 2011). The 51KO mice have not yet been characterized 
for a metabolic phenotype, but Schmidt and colleagues have reported that 51KO mice have a 
significantly lower body weight compared to wild-type littermates (Hartmann et al., 2012). 
Taken together, the parallelisms between human and 51KO mouse phenotypes support its 
validity as a model system to study the molecular mechanisms by which FKBP51 regulates 
various biological processes and/or responds to various environmental cues.  
1.8.5. FKBP51 as a Potential Therapeutic Target in the Treatment of Metabolic-
Related Disorders 
Animal and human data suggest that strategies aimed at attenuating FKBP51 may represent a 
possible basis for the development of novel therapeutics (Schmidt et al., 2012). The favorable 
stress resilient phenotype arising from loss of FKBP51 expression in mice along with the 
association between psychiatric disorders and functional FKBP5 SNPs, justifies FKBP51 as a 
possible therapeutic target in stress-related mood disorders. Importantly, highly selective 
antagonists for FKBP51, referred to as SAFit and SAFit2, have recently been described to 
enhance neurite elongation in neuronal cultures and improve stress-coping behavior in mice 
(Gaali et al., 2014). The availability of such highly selective FKBP51 antagonists provides 
the opportunity to investigate additional therapeutic prospects for FKBP51 antagonism, 
beyond the realm of psychiatric disorders. The recent preliminary evidence implicating 
FKBP51 in energy metabolism (Section 1.8.2) and its ability to regulate AKT signaling 
provide compelling indication that FKBP51 antagonism may be a novel therapeutic strategy 
in the treatment of obesity and/or T2D.  
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1.9. Rationale and Thesis Objectives 
Human and animal studies have shown that FKBP51 is able to modulate stress 
responsiveness through its ability to regulate various biological processes either as a co-
chaperone to hsp90 or independently as a scaffolding protein. Recently preliminary studies 
have furthermore emerged suggesting a role of FKBP51 in metabolic regulation. Still, there 
has been no systematic characterization of FKBP51 in the context of whole body energy 
homeostasis. The main objective of the current thesis was to establish the role of FKBP51 in 
metabolic regulation. To this end, we formulated explicit research questions to address 
whether, and to what extent, FKBP51 is involved in energy balance regulation using different 
model systems. 
 
Research Questions 
1. Does FKBP51 mediate the crosstalk between stress regulation and energy balance? 
(Chapter 2.1) 
2. Is the prenatal environmental dietary condition sufficient to modulate FKBP51 gene 
expression? (Chapter 2.2) 
3. Does loss of FKBP51 impact whole body energy metabolism, and if so how? (Chapter 
2.3 – 2.4) 
4. Is FKBP51 a prospective drug target for the treatment of obesity and/or T2D? 
(Chapter 2.3) 
5. Does FKBP51 act centrally to regulate energy homeostasis? (Chapter 2.5) 
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2.1.  The Interplay between Diet-Induced Obesity and 
Chronic Stress in Mice: Potential Role of FKBP51 
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2.3. Loss or Inhibition of FKBP51 Protects Against Diet-
Induced Metabolic Disorders by Shaping Insulin Signaling 
 
Balsevich G, Gassen NC, Häusl A, Meyer CW, Karamihalev S, Feng X, Dournes C, 
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2.3.1. Abstract
A genome wide association study demonstrated that polymorphisms within the FKBP51 gene 
(FKBP5) loci are associated with type 2 diabetes (T2D) and markers of insulin resistance 
(Pereira et al., 2014b). In line with this, the FK506 binding protein 51 (FKBP51) is a known 
negative regulator of the serine/threonine protein kinase, AKT. AKT is a central node within 
the insulin signaling pathway, and deregulation of AKT activation has been linked to the 
pathogenenesis of diabetes and obesity. In this context, FKBP51 may be an important 
regulator of insulin signaling and consequently energy and glucose homeostasis. To this end, 
we characterized the metabolic phenotype arising from FKBP51 deletion in mice (51KO) and 
addressed whether FKBP51 represents a novel therapeutic target for obesity and/or T2D 
using an FKBP51 antagonist, SAFit2. 51KO mice resisted high fat (HF) diet-induced body 
weight gain and independently presented improved glucose tolerance. Importantly, 
pharmacological inhibition of FKBP51 for 10 days improved glucose tolerance, whereas 30 
day inhibition completely recapitulated the phenotype observed in 51KO mice. Finally, we 
probed the mechanism of action by which FKBP51 affects glucose metabolism and could 
show that FKBP51 knockdown and FKBP51 blockade similarly enhance glucose uptake in 
skeletal myotubes. These data directly implicate FKBP51 in metabolic regulation and provide 
physiological and mechanistic evidence for the therapeutic potential of FKBP51 in the 
treatment of obesity and T2D.  
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2.3.2. Introduction 
There is an unmet need for therapeutic strategies targeting both obesity and T2D. 
Identification of novel multifunctional molecules, which regulate multiple key metabolic 
pathways, offers promise to overcome the current limitations in conventional therapeutic 
strategies. FKBP51 is an immunophilin protein best known as a regulator of the 
glucocorticoid receptor and consequently the physiological stress response (Ratajczak et al., 
2015). Additionally, FKBP51 regulates AKT activation, and subsequently the response to 
chemotherapy (Pei et al., 2009). Emerging evidence has linked levels of FKBP5 mRNA in 
adipose tissue to T2D-related traits (Pereira et al., 2014b). Nevertheless, whether FKBP51 
plays a critical role in whole body energy and glucose metabolism remains to be elucidated. 
For this purpose, we aimed to characterize the role of FKBP51 in energy and glucose 
homeostasis using a combination of FKBP51 knockout (51KO) mice, pharmacological 
manipulations, and mechanistic studies. 
2.3.3. Methods
Animals & Animal Housing 
The FKBP51 knockout (51KO) mouse line, used in experiments 1, 2, and 3, had been 
previously generated (Tranguch et al., 2005). C57BL/6 mice were used in experiment 4 for 
the pharmacological blockade of FKBP51 (Charles River Laboratories, Maastricht, The 
Netherlands). For all experiments, male mice between 3-4 months old were used. During 
each experiment, mice were singly-housed. Mice were maintained on a 12:12hr light/dark 
cycle, with controlled temperature (22 +/- 2°C) and humidity (55+/- 5%) conditions. Mice 
received ad libitum access to water and standard lab chow, unless otherwise specified. The 
experiments were carried out in accordance with the European Communities' Council 
Directive 2010/63/EU. The protocols were approved by the committee for the Care and Use 
of Laboratory animals of the Government of Upper Bavaria, Germany. 
Experimental Design 
Experiment 1 
Cohort 1: In the first experiment, the direct effects of FKBP51 deficiency on metabolic 
parameters were investigated in 51KO (n = 16) and WT (n = 18) mice. Body composition (fat 
and lean mass) was assessed using whole body magnetic resonance imaging (Echo-MRI, 
Houston, TX). Thereafter, mice were surgically implanted with a telemetric transponder (E-
mitter, Mini-mitter Inc., Bend, OR). Mice were allowed to recover for approximately 2 weeks 
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before any metabolic recordings were performed. Indirect calorimetry and telemetry were 
performed on mice initially under chow conditions for the assessment of energy intake, 
energy expenditure, body temperature, and home-cage activity (TSE PhenoMaster, TSE 
Systems, Bad Homburg, Germany). Each genotype groups was subsequently divided into a 
chow diet and high fat diet (HFD) (58% kcal from fat, D12331, Research Diets, New 
Brunswick, NJ, USA) group, counterbalanced for body weight in order to assess the response 
to HFD exposure. Body weight was measured throughout the experiment. After 8 weeks on 
the respective diets, 51KO and WT mice were sacrificed. Epididymal (e), inguinal (i), and 
perirenal (p) white adipose tissue (WAT) was harvested and weighed; brown adipose tissue 
(BAT) was harvested and weighed.  
Cohort 2: In a second cohort of 51KO and WT mice (n = 8 per genotype), body weight and 
body composition were examined under HF diet conditions at 30°C to minimize the effects of 
thermal stress. 
Cohort 3: A third cohort of 51KO and WT mice were exposed to 6 h of cold exposure (4°C) 
to assess cold-induced thermoregulation under both control and HF diet conditions. Briefly, 
51KO and WT males were divided into a control diet (10.5%kcal fromfat,D12329, 
ResearchDiets, Inc., New Brunswick, NJ, USA) and HFD (D12331) group (n = 11/group). 
After 5 weeks on their respective diets, cold-induced thermoregulation was monitored. 
Initially rectal body temperature was measured for 4 days prior to the cold exposure paradigm 
to habituate mice to the rectal thermocouple probe. On the 5th day, rectal temperatures were 
monitored at 0, 2, 4, and 6 h following exposure to 4°C using an Oakton Acorn Temp JKT 
Thermocouple Thermometer (Oakton Instruments, IL, USA). 
Experiment 2 
To assess the contribution of food intake on body weight regulation in 51KO and WT mice, a 
pair-feeding experiment was performed. Mice were initially singly-housed one week prior to 
the experimental onset. On day one of the pair-feeding paradigm, 51KO mice (n = 9, 51KO) 
and WT mice (n = 11, WT) received ad libitum access to HFD (D12331, Research Diets, 
New Brunswick, NJ, USA). A second group of WT mice (WT-PF) were pair-fed to the 51KO 
mice. Each day for 6 weeks, mice in the WT-PF group received restricted access to the HFD, 
defined as the amount consumed by the 51KO mice 2 days earlier. Food was weighed and 
replaced daily at 08:00. If residual food remained in the cages of WT-PF mice, it was 
weighed and removed prior to the delivery of the daily food portion. 
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Experiment 3 
In experiment 3, glucose tolerance and insulin tolerance were investigated in 51KO (n = 25) 
and WT mice (n = 18). Briefly, 51KO and WT mice were initially divided into a control diet 
group and a HF diet group counterbalanced for body weight. After 8 weeks on the dietary 
treatment, mice were subjected to a glucose tolerance test (GTT). Additionally, blood was 
collected to assess fasting insulin and glucose-stimulated insulin levels. Mice were allowed to 
recover for one week before being subjected to an insulin tolerance test (ITT). Body weight 
and food intake were measured regularly throughout the experiment. After 9.5 weeks on the 
respective diets, mice were sacrificed and tissues were collected and stored at -80°C until 
needed. 
Experiment 4 
To determine whether inhibition of FKBP51 may be an effective anti-obesity and/or diabetic 
therapeutic strategy, we treated mice for with a highly selective antagonist of FKBP51, 
known as SAFit2. Briefly, SAFit2 (20 mg/kg body weight) or vehicle were administered by 
intraperitoneal injections twice daily. SAFit2 was solubilized in vehicle containing 4% 
ethanol, 5% Tween80, 5% PEG400 in 0.9 % saline. Body weight and food intake were 
measure daily throughout the treatment periods. 
Cohort 1, sub-chronic administration: Male C57BL/6 mice were singly-housed for 2 weeks 
prior to the treatment onset. One day before the treatment period, mice were divided into a 
vehicle-treated group and a SAFit2-treated group counterbalanced for body weight (n = 
8/group). On treatment day 7 locomotor activity was assessed in the open field. On treatment 
day 8 a GTT was performed. SAFit2 levels were assessed in plasma from blood taken from at 
the time of sacrifice. Animals were sacrificed on day 10 following treatment onset. Body 
weight and food intake were measured regularly throughout the 10-day treatment schedule. 
Cohort 2, chronic administration: Four weeks before treatment onset, male C57BL/6 mice 
were divided into a control diet group (n = 25) and a HF diet group (n = 25) counterbalanced 
for body weight. One day before the treatment period, mice of each dietary group were 
further subdivided into a vehicle-treated group and a SAFit2-treated group counterbalanced 
for body weight. SAFit2 (20 mg/kg body weight) or vehicle were administered by 
intraperitoneal injections twice daily for 30 days. On treatment day 10 and again at the end of 
the treatment period (day 30), SAFit2 levels were assessed in plasma from blood taken from 
tail cut and decapitation, respectively (see below). The open field, dark-light transition, and 
elevated plus maze behavioral tests were performed on treatment days 15, 16, and 17, 
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respectively. The GTT was performed on treatment day 25 and the ITT on treatment day 29. 
Animals were sacrificed on day 31 following treatment onset; tissues were harvested and 
stored at -80°C for further analyses.   
Indirect Calorimetry 
Energy expenditure was assessed using indirect calorimetry (TSE PhenoMaster, TSE 
Systems, Bad Homburg, Germany). Briefly, animals were allowed to habituate to the indirect 
calorimetry cages for 48h before data were collected. Following 48 h of acclimatization, O2 
consumption and CO2 production were measured every 5 min for a total of 68.5 h. Indirect 
calorimetry was performed at room temperature (experiment 1, cohort 1) and at 30°C 
(experiment 1, cohort 2). O2 consumption (VO2, [ml/h]), CO2 production (VCO2, [ml/h]), 
and heat production (referred to as total energy expenditure (TEE), [kcal/24h]) were 
calculated based on the Weir equations (WEIR, 1949). The respiratory exchange ratio (RER) 
was calculated as the ratio of CO2 produced to O2 consumed (CO2/ O2). Home-cage 
locomotor activity was assessed by beam breaks using an ActiMot infrared light beam system 
within the calorimetry system. 
Assessment of Energy Expenditure Components 
The delay in acquisition between indirect calorimetry measurements and instantaneous 
locomotor activity measurements was corrected using the deconvolution procedure 
(Speakman, 2013) and was performed using a two-compartment gas diffusion model (Van 
Klinken et al., 2012), which takes into account chamber washout characteristics. Following 
deconvolution, total energy expenditure (TEE, kcal/24) was decomposed into its activity-
related energy expenditure (AEE) and resting metabolic rate (RMR). RMR was modelled in a 
time-dependent manner using a method based on penalized spline regression, allowing for the 
detection of up to four RMR frequency components per 24h (8 knots/24h)(Van Klinken et al., 
2012). Cases were excluded if the correlation between the convoluted activity and TEE did 
not reach an arbitrary cutoff of r  0.7. Model fit was assessed by visual inspection of the 
component analysis residuals. 
Intraperitoneal Glucose Tolerance Test (GTT) 
An intraperitoneal injection of D- glucose (2 g/kg body weight) was delivered to fasted mice 
(14 h fast). Blood glucose levels were measured on blood collected by tail cut at 0, 30, 60, 
and 120 min intervals following the glucose load. Glucose levels were measured using a 
handheld Contour XT glucometer (Bayer Health Care, Basel, Switzerland). Plasma was also 
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collected from blood at 0 and 30 min to assess fasting insulin and glucose-stimulated insulin 
levels, respectively.  
Intraperitoneal Insulin Tolerance Test (ITT) 
Mice were fasted for 14 h and subsequently received intraperitoneal injections of 0.5 IU/kg 
body weight of D-glucose. Blood glucose levels were assessed from tail cuts at 0, 30, 60, and 
120 min following the insulin load. Glucose levels were measured using a handheld Contour 
XT glucometer (Bayer Health Care, Basel, Switzerland). 
Behavioral Analyses 
All behavioral tests were performed during 08:00 and 12:00 (Experiment 4). General 
locomotor activity was examined in an empty open field arena over 15 min under 15 lux 
illumination. Anxiety-related behaviors were assessed using the elevated plus maze and dark-
light transition tests as previously described (Schmidt et al., 2009). Each test was videotaped 
by an overhead camera and analyzed using the automated video-tracking software 
ANYmaze4.9 (Stoelting, Wood Dale, IL, USA).  
Tissue Collection 
Mice were anesthetized with isoflurane and immediately sacrificed by decapitation. Basal 
trunk blood was collected and subsequently processed (plasma was collected and stored at -
20°C). Skeletal muscle (extensor digitorum longus (EDL) and soleus), WAT (inguinal (i), 
epididymal (e), and perirenal (p)), liver, and hypothalamus were collected and stored at -80°C 
until used. 
Hormone Quantification 
Plasma insulin levels were determined using a mouse metabolic magnetic bead panel 
(Millipore Corp. Billerica, Massachusetts; sensitivity: insulin 14pg/ml). For the assessment of 
fasting insulin levels, blood was collected 14 h following an overnight fast by tail cut. 
Similarly, glucose-stimulated insulin levels were measured from plasma taken from blood 
collected 30 min following glucose load during the glucose tolerance test. 
SAFit2 Quantification 
The concentration of the FKBP51 antagonist SAFit2 on day 10 and 30 of treatment was 
quantified from plasma by LCMS/ MS. Briefly, plasma was analyzed using the combined 
high-performance liquid chromatography/mass spectrometry (HPLC/MS-MS) technique. 
Analysis was performed using an Agilent 1100 Series (Agilent, Waldbronn, Germany) liquid 
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chromatograph which was interfaced to the ESI source of an Applied Biosystems API 4000 
(ABSciex, Darmstadt, Germany) triple quadrupole mass spectrometer. All samples were 
added to Ostro protein precipitation and phospholipid removal plates (Waters, Eschborn, 
Germany). Deuterated clomipramine (Clomi-D3) was used as internal standard. 
Chromatography was performed using a gradient elution in an Accucore RP-MS 2,6m 
column (2.1 x 50 mm, Thermo Scientific, Dreieich, Germany) at a flow rate of 0.3ml/min and 
30 °C.  
Cell Lines 
C2C12 myoblasts were maintained in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% fetal bovine serum and 1x penicillin streptomycin antibiotics at 37 
°C in a humidified atmosphere with 5% CO2. Once the cells reached ~90% confluency, 
C2C12 myoblasts were infected with adeno-associated viral (AAV) vectors expressing either 
GFP control or shRNA against FKBP51. A multiplicity of infection (MOIs) of 5 x 104 was 
used. Cells were induced to differentiate 8 h after infection for 3 days before the examination 
of glucose uptake. Differentiation was induced by switching the growth medium to DMEM 
containing 2% horse serum for 3 days. 
Glucose Uptake 
Basal and insulin-stimulated glucose uptake in differentiated C2C12 myotubes was 
examined. Briefly, C2C12 myotubes were serum-starved in low glucose (1000 mg/L) DMEM 
for 4h, and then incubated in Krebs-Ringer-HEPES (KRH) buffer (136 mM NaCl, 4.7 mM 
KCl, 10 mM sodium phosphate buffer, 1 mM MgSO4, 1 mM CaCl2, 10 mM HEPES, pH 7.4, 
0.2% BSA) for 10 min. Cells were stimulated with insulin (100 nM) or left unstimulated for 
1h. Glucose uptake was induced by the addition of KRH buffer containing 100 μM 2-deoxy-
D-[1,2-3H]glucose, 2 μCi/ml (Perkin Elmer) to each well. 4 minutes thereafter, the reactions 
were terminated by washing the cells with ice-cold PSB containing 10μM cytochalasin B 
(inhibitor of membrane transporter-dependent glucose transport), and then 2 additional 
washes with ice-cold 1x PBS. Cells were lysed with 0.1M NaOH for 30min, and the 
incorporated radioactivity was determined by liquid scintillation counting. 2-deoxy-D-[1,2-
3H]glucose uptake was furthermore normalized to total protein content assessed by the BCA 
assay (BCA Protein Assay Kit, Life Technologies, Darmstadt, Germany). 
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Western Blot Analysis 
Tissues were homogenized in lysis buffer containing 62.5 mM Tris-HCl, 2% SDS, and 10% 
sucrose supplemented with protease (Sigma, P2714) and phosphatase (Roche, 04906837001) 
inhibitor cocktails, and subsequently centrifuged at 12,00 x g to remove cell debris. Lysates 
were sonicated three times, and protein concentrations were measured using the BCA assay 
(BCA Protein Assay Kit, Life Technologies, Darmstadt, Germany). After dilution, protein 
samples (40 μg) were heated for 5 min at 95°C in loading buffer. Equal amounts of proteins 
were separated by SDS-PAGE and electro-transferred onto nitrocellulose membranes. Non-
specific binding was blocked in Tris-buffered saline, supplemented with 0.05% Tween 
(Sigma, P2287) and 5% non-fat milk for 1 h at room temperature and subsequently blots were 
incubated with primary antibody (diluted in TBS/0.05% Tween) overnight at 4 ºC. For a list 
of primary antibodies used, please refer to Supplementary Table S 1. The following day, blots 
were washed and probed with the respective horseradish peroxidase secondary antibody for 1 
h at room temperature. Immuno-reactive bands were visualized using ECL detection reagent 
(Millipore, Billerica, MA, USA, WBKL0500). Band intensities were evaluated with the 
ChemiDoc Imaging System (Bio-Rad).  
Quantification of Protein Data 
The level of each phosphorylated protein was normalized to its respective non-
phosphorylated protein. For total protein content, actin was used as an internal control. 
Statistical Analysis 
Data were analyzed by Student’s t-tests or ANOVA, where appropriate, using IBM SPSS 
Statistics 18 software (IBM SPSS Statistics, IBM, Chicago, IL, USA). Data were transformed 
for ANOVA to meet the assumption of homogeneity of variance when required 
(Supplementary Table S 2). Repeated measures ANOVA was used for all body weight 
progression, GTT, and ITT data, in which the degrees of freedom were corrected for deviance 
from sphericity (Greenhouse–Geisser) for within-subjects comparisons. A Bonferroni post 
hoc test was used for ANOVA tests to determine statistical significance between individual 
groups. The decomposition of TEE into AEE and RMR was performed in MATLAB (The 
MathWorks, Natick, MA, USA) using a custom-designed toolbox graciously provided by JB 
van Klinken (Bioinformatics Center of Expertise, Leiden University Medical Center, Leiden, 
The Netherlands). Body weight was included as a covariate in the analyses of energy 
expenditure (Arch et al., 2006). Statistical analyses for all energy expenditure outcome 
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variables, RER, home-cage activity, food intake, water intake, and body temperature were 
performed on either 24-hour averages. Statistical significance was set at p < 0.05; a statistical 
tendency was set at p < 0.1. For interactions at p < 0.1, we also examined lower order main 
effects. Data are presented as the mean +/- S.E.M. 
2.3.4. Results
In order to examine the role of FKBP51 in energy and glucose homeostasis we initially 
characterized the metabolic outcomes arising in FKBP51 knockout (51KO) mice. We found 
that 51KO mice fed a chow diet showed a modest body weight phenotype, and furthermore 
presented reduced adiposity and increased lean mass compared to wild-type (WT) littermates 
(Figure 1.3.1a). Strikingly, when challenged with HF diet exposure for 8 weeks, 51KO mice 
were protected from both HF diet-induced weight gain and increased adiposity (Figure 2.3.1b 
& c). Loss of FKBP51 likewise counteracted diet-induced obesity under thermoneutral 
conditions (30°C), arguing against a thermoregulatory basis of the phenotype (Supplementary 
Figure S 1). Indirect calorimetry revealed that the HF diet resistant phenotype observed in 
51KO mice was accompanied by a modest increase in total energy expenditure, as a result of 
an increased resting metabolic rate (RMR) (Supplementary Figure S 2). In addition, 51KO 
mice presented a modest decrease in their RER and an increase in their home-cage activity. 
By contrast, food intake was not affected by total loss of FKBP51. To confirm a lack of 
FKBP51 effect on feeding behavior, a separate pair-feeding experiment was performed, in 
which a cohort of WT mice was pair-fed to 51KO mice. This experiment again revealed no 
genotype effect on energy intake (Supplementary Figure S 3). No additional outcomes of 
FKBP51 on energy homeostasis were identified using the comprehensive lab animal 
monitoring system (Supplementary Figure S 2).  
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Figure 2.3.1 Genetic ablation of FKBP51 prevents HF diet-induced weight gain 
(a) 51KO mice presented lowered body weight (T36 = 2.577, p = 0.014), decreased fat mass (T26.7 = 
4.584, p < 0.001), and increased lean mass (T36 = -3.870, p < 0.001) compared to WT littermates at 
the onset of the dietary feeding period (b) 51KO mice weighed significantly less than WT mice 
throughout the 8 week dietary treatment (Time x Genotype: F(1, 50.7) = 16.328, p < 0.001; 
Genotype: F(1, 30) = 17.924, p < 0.001) and at the experimental end (Genotype: F(1, 30) = 19.658, 
p < 0.001). Interestingly, whereas WT mice were susceptible to HF diet-induced weight gain, 
51KO mice were not as interpreted from weight progression (Time x Genotype x Diet: F(1, 50.7) = 
3.370, p = 0.050) and final body weight (following 8 weeks on respective diets) (Diet: F(1, 30) = 
9.116, p = 0.005, Bonferroni correction). (c) After 8 weeks on the dietary treatment, 51KO mice 
presented decreased fat pad weights for eWAT (Genotype: F(1, 30) = 23.195, p < 0.001), iWAT 
(Genotype: F(1, 30) = 22.979, p < 0.001), and pWAT (Genotype: F(1, 22) = 10.456, p = 0.004) 
compared to WT counterparts. Nevertheless, HF diet exposure significantly increased fat pad mass, 
regardless of genotype (Diet for eWAT: F(1, 30) = 25.607, p < 0.001; iWAT: F(1, 30) = 16.942, p 
< 0.001; pWAT: F(1, 22) = 12.255). +P < 0.05, ++P < 0.01, +++P < 0.001; #P < 0.05, ##P < 0.01, ###P 
< 0.001; + significant genotype effect; # significant diet effect. 
 
Research Articles
 
72 
 
To determine the effects of FKBP51 on glucose metabolism and insulin sensitivity, we 
performed glucose tolerance and insulin tolerance tests in a separate cohort of 51KO and WT 
mice. Body weight data were consistent with our previous experiments (Supplementary 
Figure S 4). FKBP51 deletion lowered fasting glucose (Figure 2.3.2a) and remarkably 
improved glucose tolerance under control and HF dietary conditions (Figure 2.3.2b – c). 
Interestingly, the levels of fasted insulin and glucose-stimulated insulin were not different 
between 51KO and WT mice (Figure 2.3.2d – e), indicating that differences in insulin 
secretion do not contribute to the improved glucose tolerance phenotype. During an insulin 
tolerance test, 51KO mice presented a prolonged response to insulin under control and HF 
dietary conditions, despite the fact that both 51KO and WT mice remained vulnerable to HF 
diet-induced insulin intolerance (Figure 2.3.2f – g). 
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Figure 2.3.2 Genetic ablation of FKBP51 improves glucose tolerance 
(a) Blood glucose following a 14 h fast was significantly lower in 51KO mice compared to WT 
mice (Genotype: F(1, 37) = 5.197, p = 0.028). (b) In the GTT, a HF diet impaired glucose tolerance 
in WT mice but not in 51KO mice (HF group: Time x Genotype: F(1, 38.9) = 4.440, p = 0.018, 
Genotype: F(1, 19) = 10.971, p = 0.004; Chow group: Genotype: (F(1, 17) = 6.567, p = 0.020). (c) 
The area under the glucose curve illustrates the effect of genotype (F(1, 36) = 17.004, p < 0.001) 
and diet (F(1, 36) = 4.628, p = 0.038) on glucose tolerance. (d, e) Fasted insulin and glucose-
stimulated insulin were significantly elevated from HF diet exposure (Fasted: F(1, 35) = 10.653, p 
= 0.004; Stimulated: F(1, 37) = 9.228, p = 0.004) independent of genotype. (f) In HF diet-fed mice, 
loss of FKBP51 significantly reduced insulin tolerance (Time x Genotype: F(1, 60) = 6.031, p = 
0.004). Importantly blood glucose remained significantly lower 120 min following insulin 
administration on account of FKBP51 deletion under both chow conditions (T16 = 3.286, p = 
0.005) and HF diet conditions (T20 = 2.466, p = 0.023). (g) The Area under the glucose curve for 
ITT demonstrates the strong diet effect (F(1, 34) = 19.877, p < 0.001) and a trend for genotype 
(F(1, 34) = 3.851, p = 0.058). +P < 0.05, ++P < 0.01, +++P < 0.001; #P < 0.05, ##P < 0.01, ###P < 
0.001; + significant genotype effect; # significant diet effect. 
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Due to the improved metabolic phenotype of 51KO mice, we subsequently assessed the 
therapeutic efficacy of pharmacological blockade of FKBP51. Importantly, a highly selective 
antagonist for FKBP51, known as SAFit2, has recently been developed (Gaali et al., 
2015;Hartmann et al., 2015). The authors described improved neurite outgrowth in neuronal 
cultures and improved stress coping behavior in mice from SAFit2 treatment, with possible 
therapeutic potential in the treatment of stress-related psychiatric disorders. In the current 
study, we determined the therapeutic efficacy of FKBP51 antagonism in mice on metabolic 
parameters. At first, SAFit2 (20mg/kg) was administered twice daily for 10 days to adult 
C57BL/6 mice by intraperitoneal injections under chow-fed conditions. Although 10 days of 
FKBP51 antagonism yielded no body weight phenotype, there was a marked lowering of 
glucose tolerance assessed on treatment day 8 (Figure 2.3.3a – b). To determine whether a 
longer treatment period was required to achieve a body weight phenotype, a second cohort of 
C57BL/6 mice were treated with SAFit2, this time for 30 days under both control and HF diet 
conditions. This injection schedule resulted in high SAFit2 plasma levels and minimal inter-
animal variability (Supplementary Figure S 5). At the onset of treatment, following 4 weeks 
of dietary exposure, there was no difference in body weight between treatment groups 
(Supplementary Figure S 6). However, we found that 30 days of SAFit2 administration led to 
a reduction in body weight under both control and HF diet conditions (Figure 2.3.3c). 
Furthermore FKBP51 antagonism protected against HF diet-mediated glucose intolerance 
(Figure 2.3.3d). There was however no effect of SAFit2 on insulin tolerance or on locomotor 
activity tested in the open field (Supplementary Figure S 7). Importantly, there were no 
unwanted side-effects of FKBP51 antagonism on behavioral readouts tested in the elevated 
plus maze and dark-light transition tests (Supplementary Figure S 8). Taken together, these 
results clearly demonstrate that pharmacological blockade of FKBP51 phenocopies the 
effects of FKBP51 genetic ablation and furthermore demonstrate the therapeutic potential of 
SAFit2 in the treatment of obesity and T2D. 
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Figure 2.3.3 Pharmacological inhibition of FKBP51 parallels the metabolic effects 
resulting from genetic ablation of FKBP51 
(a) 10-day SAFit2 treatment had no significant effect on body weight. (b) Despite no effect on 
body weight, SAFit2 treatment significantly lowered glucose tolerance as reflected in the glucose 
AUC for the GTT measured on treatment day 8 (T13 = 2.469, p = 0.028). (c) At the experimental 
end point (following 30 days of treatment), mice treated with SAFit2 weighed significantly less 
than their diet counterparts (Treatment: F(1, 44) = 6.148, p = 0.017). Nevertheless mice fed the HF 
diet remained significantly heavier independent of treatment (Diet: F(1, 44) = 5.380, p = 0.025). (d) 
The extended SAFit2 treatment schedule furthermore protected against HF diet-induced impaired 
glucose tolerance as reflected in the glucose AUC measured on day 25 (Diet x Treatment: F(1, 42) 
= 2.954, p = 0.093, Bonferroni correction). +P < 0.05; #P < 0.05; + significant treatment effect; # 
significant diet effect. 
To determine the mechanism by which FKBP51 may regulate glucose homeostasis and 
consequently glucose tolerance, we initially examined the phosphorylation status of critical 
nodes along the insulin signaling cascade as a marker of insulin signaling activation. As we 
found a strong effect of FKBP51 loss on glucose tolerance without any alterations of 
circulating insulin levels, we hypothesized that intracellular insulin signaling is enhanced 
following total loss of FKBP51. We found that insulin sensitivity (as reflected through the 
phosphorylation status of p70S6K, IRS-1, and AKT) was markedly increased in skeletal 
muscle of 51KO mice, whereas insulin activation in adipose tissue remained unchanged 
(Figure 2.3.4a – b). Indeed, skeletal muscle accounts for an estimated 80% of postprandial 
glucose disposal and is regarded as a principal site responsible for the maintenance of glucose 
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homeostasis (DeFronzo et al., 1985;Zierath and Wallberg-Henriksson, 2002). Therefore, as a 
natural next step we examined glucose uptake in differentiated C2C12 myotubes. 
Knockdown of FKBP51 in differentiated skeletal myotubes enhanced glucose uptake (Figure 
2.3.4c). Importantly, inhibition of FKBP51 using SAFit2 similarly increased glucose uptake 
in C2C12 cells (Figure 2.3.4d). Thus the beneficial effects of FKBP51 inhibition on glucose 
homeostasis require enhanced insulin signaling. 
Figure 2.3.4 Loss of FKBP51 sensitizes insulin signaling and enhances glucose uptake 
(a) In EDL skeletal muscle of 51KO mice, insulin signaling was enhanced compared to WT mice 
as assessed by pAKT (T8.7 = -3.005, p = 0.015), pIRS1 (T16 = -2.660, p = 0.017), and pp70S670 
(T16 = -4.491, p < 0.001) phosphorylated protein expression. (b) This outcome was specific for 
skeletal muscle, as phosphorylated protein expression was not changed in white adipose tissue 
(WAT) depots on account of genotype. (c) 2-deoxyglucose uptake is significantly enhanced in 
C2C12 myotubes in which FKBP51 has been knocked down (T4 = 4.674, p = 0.009). (d) Similarly, 
FKBP51 blockade with SAFit2 significantly enhanced 2-deoxyglucose uptake in C2C12 myotubes 
(T3 = 4.446, p = 0.021). Data are expressed as relative fold change compared to wild-type 
condition. +P < 0.05, ++P < 0.01 +++P < 0.001; + significant genotype/treatment effect. 
2.3.5. Discussion 
Here we describe for the first time that loss of FKBP51 in mice protects against diet-induced 
obesity and markedly lowers glucose tolerance under both control and HF diet conditions. 
The effects of FKBP51 on glucose homeostasis are driven by enhanced insulin signaling 
within skeletal muscle and consequently heighted glucose disposal. Moreover, administration 
of a recently developed selective antagonist of FKBP51 mimicked the metabolic phenotype 
arising from total genetic loss of FKBP51. FKBP51 blockade produced a modest body weight 
phenotype and a strong effect on glucose tolerance as early as 8 days following treatment 
onset. From these data, we conclude that FKBP51 is an integral component of energy and 
glucose homeostatic regulation, particularly in response to nutritional changes. The improved 
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metabolic outcomes following systemic administration of a selective antagonist of FKBP51, 
SAFit2, offers new opportunities for drug development. 
The effects of FKBP51 on body weight are likely driven by increases in RMR without 
compensatory increases in energy intake. Nevertheless, the present study does not allow one 
to identify the mechanism underlying the increased RMR. Rather the focus of the current 
study was to characterize the striking association in humans between single nucleotide 
polymorphisms with the FKBP5 gene loci and traits related to T2D (Pereira et al., 2014b). 
Our data highlight a fundamental role for FKBP51 in the regulation of glucose homeostasis. 
Glucose tolerance in 51KO is improved even in the absence of a strong body weight 
phenotype, under control diet settings. This suggests that the FKBP51-dependent 
improvement of glucose homeostasis is not secondary to body weight. In line with these 
findings, we found that loss of FKBP51 sensitizes the insulin signaling pathway. 
Interestingly, FKBP51-dependent effects on insulin signaling was highly tissue-specific, in 
which FKBP51-dependent increases in insulin signaling was limited to skeletal muscle. In 
this context, we also found that glucose uptake in mouse myotubes is enhanced on account of 
either FKBP51 knockdown or FKBP51 pharmacological blockade. 
It has been previously shown that FKBP51 binds to AKT, a serine-threonine kinase within 
the insulin signaling cascade, to ultimately favor AKT inactivation (Pereira et al., 2014b). 
Through this interaction, FKBP51 was associated with tumor growth and chemotherapy 
responsiveness. We have extended such previous findings by demonstrating that not only are 
AKT and downstream targets of AKT regulated in an FKBP51-dependent manner (reflected 
by the phosphorylation states of AKT downstream effector proteins), but we have also 
demonstrated that FKBP51 exerts an effect on upstream signaling, whereby 51KO mice 
displayed enhanced activation of the insulin receptor substrate 1 (IRS-1). Within the insulin 
signaling pathway, the IRS-1 represents a critical node for the regulation of insulin 
sensitivity, and dysregulation at IRS-1 is often featured in T2D (Taniguchi et al., 2006). 
Tissue responsiveness to insulin in fact requires IRS-1 and IRS-2, which function to couple 
insulin receptor activation to the recruitment and activation of downstream signaling 
molecules including AKT (Copps and White, 2012). IRS-1 contains over 50 possible serine-
phosphorylation sites, whose phosphorylation status governs IRS-1 signaling. We specifically 
examined phosphorylation of serine-307 (S307), which has been shown to promote insulin 
sensitivity in mice (Copps et al., 2010). Our data support this notion such that 51KO mice 
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present increased S307 IRS-1 phosphorylation in skeletal muscle which is accompanied by 
enhanced downstream insulin signaling and improved glucose tolerance. 
An important question raised by this study is how exactly FKBP51 acts within distinct 
cellular/tissue environments to affect whole body energy and glucose homeostasis. Previous 
studies have already alluded to the importance of tissue-specific actions of FKBP51 
(Hartmann et al., 2015;Toneatto et al., 2013). Here we extend our current understanding of 
the tissue-specific actions of FKBP51 to include FKBP51-dependent regulation of the insulin 
signaling exclusively within skeletal muscle. Despite microarray-based data demonstrating 
that skeletal muscle shows the second strongest expression profile of FKBP51 across all 
tissues examined (Su et al., 2004), to our knowledge, the current study is the first to define a 
skeletal muscle-specific role of FKBP51. These data, along with our FKBP51-dependent 
glucose uptake findings in cultured myotubes, suggest the possibility that targeted disruption 
of FKBP51 specifically within skeletal muscle may be sufficient to improve glucose 
homeostasis. 
Together, these findings define a novel role of FKBP51-dependent regulation of glucose 
uptake and whole body glucose homeostasis. In addition, the positive effects of FKBP51 
pharmacological blockade on both body weight and glucose tolerance suggests a potential 
opportunity to employ FKBP51 antagonists for the treatment of obesity and T2D. 
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2.3.6. Supplementary Data 
 
Supplementary Figure S 1 Genetic ablation of FKBP51 protects against diet-induced 
obesity under thermoneutral conditions 
(a) Over 8 weeks of HF diet exposure at 30°C, 51KO mice are still resistant to HF diet-induced 
weight gain (Time x Genotype: F(1, 21.2) = 18.567, p < 0.01; Genotype: F(1, 14) = 9.346, p = 
0.009) and (b) adiposity (eWAT: T14 = 5.054, p < 0.001; iWAT: T14 = 3.313, p = 0.005). Data are 
expressed as means ± s.e.m. +P < 0.05, ++P < 0.01, +++P < 0.001; + significant genotype effect 
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Supplementary Figure S 2 Metabolic phenotype in 51KO transgenic mice 
Initially metabolic readouts were assessed in WT mice (n = 17) and 51KO mice (n = 16) under 
chow conditions in CLAMS (Comprehensive Lab Animal Monitor Systems). (a) When bodyweight 
was held constant, total energy expenditure (TEE) was higher in the chow-fed 51KO animals 
measured across 24h (Genotype: F(1, 28) = 7.275, p = 0.012). Decomposition of TEE into its 
resting (RMR) and activity-related (AEE) components revealed that the observed TEE difference 
was due to increased RMR in the 51KO animals measured over 24h (Genotype: F(1, 27) = 7.495, p 
= 0.011). Activity-related energy expenditure did not differ between genotypes as assessed across 
24h (Genotype: F(1, 27) = 1.288, ns). (b) Loss of FKBP51 furthermore decreased the average 
respiratory exchange ratio (RER) activity (Genotype: T25 = -2.507, p = 0.019) and (c) increased 
the average home-cage (Genotype: T27 = -2.301, p = 0.029) assessed across 24h. There was 
however no effect of genotype on either water consumption (d), food intake (e) or body 
temperature (f) assessed across 24 h. (g) In order to ensure there was no effect on body temperature 
regulation, a separate cohort of mice were examined for cold-induced rectal temperature changes 
following exposure to 4°C under control and HF diet conditions. Repeated measures ANOVA 
revealed neither a genotype effect nor a diet effect on the ability to regulate body temperature 
following short-term (6h) cold exposure. +P < 0.05; + significant treatment effect. 
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Supplementary Figure S 3 Food intake does not contribute to the diet-resistant 
phenotype in 51KO mice 
A pair-feeding experiment was performed over 6 weeks to determine whether genotype-dependent 
differences in food intake exist. (a) At the experiment onset, all mice were placed on a HF diet. 
51KO control and WT ad libitum mice had free access to food, whereas WT PF were pair-fed to 
the 51KO mice. The WT PF group continued to gain weight despite pair-feeding (Time x 
Experimental group: F(1, 45.5) = 4.528, p = 0.006). (b) At the end of the pair-feeding paradigm 
51KO mice weighed significantly less compared to WT mice (Experimental group: F(1, 28) = 
4.410, p = 0.022, Bonferroni correction). Data are expressed as means ± s.e.m. +P < 0.05, TP < 0.1; 
+ 51KO mice are significantly different from WT control mice. 
 
 
Supplementary Figure S 4 Genetic ablation of FKBP51 prevents HF diet-induced 
weight gain observed across 2 independent experiments 
In an independent experiment used to assess glucose and insulin tolerance, 51KO mice presented 
the same body weight phenotype compared to WT mice as reported in Experiment 1. (a) 51KO 
mice weighed significantly less than WT mice throughout the 8 week dietary treatment (Time x 
Genotype: F(1, 93.0) = 9.807, p < 0.001; Genotype: F(1, 41) = 8.057, p = 0.001) and (b) at the 
experimental end (Genotype: F(1, 42) = 10.262, p < 0.001). Furthermore, a tendency was observed 
indicating that WT mice were susceptible to HF diet-induced weight gain compared to 51KO mice 
as interpreted from body weight progression (Time x Genotype x Diet: F(1, 93.0) = 2.040, p = 
0.087). TP < 0.1, + ++P < 0.001; + significant treatment effect; T significant trend for diet. 
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Supplementary Figure S 5 Plasma SAFit2 levels 
Administration of SAFit2 by intraperitoneal injections resulted in high SAFit2 plasma levels and 
minimal inter-animal variability. SAFit2 was delivered twice daily at 20 mg/kg. Blood was 
collected by tail cut 5 h post-injection for the measurement of SAFit2 in all SAFit-treated mice (n = 
24) Measurement was performed on day 10 and day 30 of treatment schedule. SAFit2-treated mice 
showed meaningful levels of plasma SAFit2. 
 
 
 
Supplementary Figure S 6 Body weight progression preceding SAFit2 treatment 
4 weeks before SAFit2 treatment onset, mice were randomly assigned to either the control diet or 
HF diet group. (a) Exposure to the HF diet resulted in a significant increase in body weight 
progression (Time x Diet: F(1, 121.2) = 10.250, p < 0.001; Diet: F(1, 47) = 22.397, p < 0.001). (b) 
At treatment onset, mice were subdivided into treatment groups counterbalanced by body weight, 
and therefore within each dietary group there was no difference in body weight. Nevertheless, mice 
exposed to 4 weeks of HF diet weighed significantly more than control diet-fed mice (Diet: F(1, 
45) = 25.341, p < 0.001). #P < 0.05, ###P < 0.001; # significant diet effect. 
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Supplementary Figure S 7 Administration of SAFit2 by intraperitoneal injections had 
no effect on locomotor activity or insulin tolerance 
(a) SAFit2 treatment had no effect on total distance traveled in an open field, although HF diet 
exposure significantly reduced locomotor activity (Diet: F(1, 45) = 10.942, p = 0.002). (b) Insulin 
tolerance is expressed as the area under the glucose curve (AUC). Although insulin tolerance was 
significantly impaired by HF diet exposure, there was no improvement on account of SAFit2 
treatment (Diet: F(1, 43) = 8.376, p = 0.006). Data are expressed as means ± s.e.m. ##P < 0.01; # 
significant diet effect. 
 
 
 
Supplementary Figure S 8 Administration of SAFit2 by intraperitoneal injections had 
no undesirable behavioural side effects 
30-day treatment of SAFit2 had no effect on anxiety-like behavior examined in both the dark-light 
transition test (a) and the elevated plus maze test (b). By contrast, exposure to a HF decreased the 
time spent in the lit compartment of the dark-light test (Diet: F(1, 45) = 4.817, p = 0.033). 
Altogether these findings indicate that there are no undesirable behavioral outcomes on account of 
SAFit2 treatment. #P < 0.05; # significant diet effect. 
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Supplementary Table S 1 List of all primary antibodies 
 
 
Supplementary Table S 2 Data transformations 
Data transformations used to generate data with homogeneous variance. Data represented in all 
Figures reflect the non-transformed data. 
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2.4. FKBP51 Enhances AMPK Inhibition of mTOR: A 
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2.4.1. Abstract
Although 5’-AMP-activated protein kinase (AMPK) is an established regulator of cellular 
and whole body energy metabolism, its own regulation is incompletely understood. FK506 
binding protein 51 (FKBP51) is known to interact with several serine/threonine kinases but 
whether it interacts with AMPK is unknown. Given the recently identified role of FKBP51 in 
whole body energy metabolism, we investigated whether FKBP51 regulates AMPK, and 
furthermore addressed whether FKBP51 is required for AMPK-mediated regulation of 
metabolic outcomes by employing metformin (an AMPK agonist) in wild-type (WT) and 
FKBP51 knockout (51KO) mice. We demonstrate that FKBP51 binds to various AMPK 
subunits and to the direct downstream target of AMPK, tuberin (TSC2), which is a negative 
regulator of mTOR. Interestingly, loss of FKBP51 impairs the ability of metformin to 
suppress downstream mTOR signaling in both in vitro and in vivo models. Nevertheless, 
metformin was equally effective at lowering fasting blood glucose in WT and 51KO mice. In 
conclusion, we establish FKBP51 as a novel constituent of the AMPK heterocomplex and 
consequently as a novel regulator of the AMPK-mTOR signaling axis. 
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2.4.2. Introduction 
5’-AMP-activated protein kinase (AMPK) is a highly conserved serine (ser)/threonine (thr) 
kinase that acts as an energy sensor to regulate cellular and whole body energy metabolism 
(Hardie, 2015). As a heterotrimeric complex containing a catalytic -subunit and regulatory  
and  subunits, AMPK is activated by an increase in the cellular AMP-to-ATP ratio and thus 
signals low energy status. Any stimulus, including stressors, glucose deprivation, muscle 
contraction, and exercise, that increases ATP consumption activates AMPK. Full activation 
of AMPK not only requires allosteric activation by 5’-AMP, but also requires 
phosphorylation on Thr-172 within the -subunit by upstream kinases, including the ser/thr 
protein kinase LKB1 (liver kinase B1) (Lizcano et al., 2004). Once activated AMPK 
phosphorylates multiple downstream targets, whose concerted actions promote catabolic 
(ATP-generating) pathways, while inhibit anabolic (ATP-consuming) pathways. Therefore 
the appropriate regulation of AMPK and the upstream LKB1 kinase activity is critical for 
health and disease (Steinberg and Kemp, 2009). 
LKB1 is active when in complex with Ste-20-related kinase adaptor (STRAD) and calcium-
binding protein 39 (CAB39, also known as MO25). Within the LKB1-STRAD-MO25 
complex, LKB1 phosphorylates AMPK, increasing AMPK activation over 50-fold compared 
to AMP allosteric activation alone (Lizcano et al., 2004). The LKB1 complex is known to 
possess high basal activity, and thus its capacity to phosphorylate Thr-172 within the -
subunit of AMPK is regulated by the binding of AMP to AMPK, which induces a 
conformational change that favors LKB1-dependent Thr-172 phosphorylation (Hardie, 2015). 
However it is only recently that studies have identified that both the LKB1 complex itself and 
the LKB1-AMPK interaction are regulated by additional extrinsic proteins. In particular, it 
was demonstrated that Skp2-SCF ubiquitin ligase governs LKB1 activity by maintaining the 
LKB1-STRAD-MO25 complex integrity (Lee et al., 2015). Furthermore it has been shown 
that an adapter protein, axin, facilitates the interaction between the LKB1 complex and 
AMPK (Zhang et al., 2013). Whether additional, unidentified extrinsic proteins regulate 
LKB1-AMPK signaling remains unclear. 
The mammalian target of rapamycin (mTOR) is a ser/thr protein kinase that lies downstream 
of AMPK signaling (Inoki et al., 2012). The mTOR signaling cascade acts as a key integrator 
for nutrient and growth factor signals. In contrast to AMPK, mTOR activity favors catabolic 
metabolism. The AMPK-mTOR signaling pathways are intimately connected through the 
tuberous sclerosis complex (TSC), comprising TSC1 (hamartin) and TSC2 (tuberin) 
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(Wullschleger et al., 2006). AMPK phosphorylates Ser-1387 within the TSC2 protein to 
activate the TSC1/2 complex (Inoki et al., 2003b). In turn the activated complex acts 
indirectly to inhibit mTOR (Inoki et al., 2003a). Taken together, the balance between AMPK 
and mTOR signaling is important for maintaining cellular and whole body energy 
homeostasis.  
We (unpublished data, Chapter 2.3) and others (Pereira et al., 2014b) have identified the 
FK506 binding protein 51 (FKBP51) as a novel molecule in the regulation of whole body 
energy metabolism. FKBP51 is an immunophilin protein that is best characterized as a co-
chaperone to the Hsp90 complex and a regulator of steroid receptor signaling (Riggs et al., 
2003;Wochnik et al., 2005). FKBP51 has also been shown to directly bind several ser/thr 
protein kinases to ultimately affect their signaling cascade (Gassen et al., 2015;Pei et al., 
2009). For example, Pei et al. reported that FKBP51 acts as a scaffolding protein between the 
ser/thr protein kinase, AKT, and a negative regulator of AKT, PHLPP to ultimately inhibit 
AKT signaling (Pei et al., 2009). Interestingly, systematic characterization of the interaction 
network of various co-chaperone proteins, including FKBP51, described LKB1 as one of the 
strongest binding partners of FKBP51 (Taipale et al., 2014). Nevertheless, this interaction 
was not characterized any further. Based on the ability of FKBP51 to interact with LKB1, 
several additional ser/thr protein kinases, and due to its association with whole body energy 
metabolism, we sought to examine whether FKBP51 regulates the AMPK-mTOR signaling 
axis. 
2.4.3. Methods
Cell lines and Culture Conditions 
Human embryonic kidney cells (HEK-293; ATCC, CRL-1573) and mouse embryonic 
fibroblasts (MEFs) were cultured in DMEM (Gibco) supplemented with 10% FCS and 100 
units/ml penicillin and streptomycin at 37°C and 5% CO2. FKBP51 knockout (51KO) MEFs 
were derived from 51KO mice and have been previously described (Touma et al., 2011). 
Cells were passaged by trypsinization once the cells had reached ~80% confluency. 
Co-Immunoprecipitation (coIP) 
Immunoprecipitations of endogenous proteins were performed in HEK-293 cells. Briefly, the 
cells were lysed in coIP buffer containing 20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1mM 
EDTA, 0.5% Igepal complemented with protease inhibitor cocktail (Sigma, P2714), followed 
by incubation for 20 min at 4 °C while shaking on an overhead shaker. To clear the lysate, 
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samples were centrifuged (14,000xg for 20 min at 4°C) and protein concentrations were 
determined. 500 μg of lysate was incubated overnight with 2 μg of the appropriate IP-
antibody (antibodies for each AMPK-subunit) (See Table 1) at 4 °C. 20 μL of protein G 
dynabeads (Invitrogen, 100-03D) was blocked with bovine serum albumin and subsequently 
added to the lysate-antibody mix and allowed to incubate at 4 °C for 3 h in order to mediate 
binding between the dynabeads and the antibody-antigen complex of interest. The beads were 
washed three times with ice-cold phosphate-buffered saline (PBS). The protein-antibody 
complexes were eluted with 60 μL Laemmli loading buffer. Thereafter the eluate was boiled 
for 5 min at 95 °C. 2-5 μL of each immunoprecipitate reaction product was separated by 
SDS-PAGE and electro-transferred onto nitrocellulose membranes. For assessing protein 
complexes, immunoblotting against FKBP51 was performed. 
Co-immunoprecipitations (CoIPs) of FLAG-tagged TSC2 with endogenous FKBP51 was 
performed in HEK-293 cells. 5x106 cells were electroporated with 5 μg of a FLAG-tagged 
TSC2 expression plasmid using a GenePulser (Bio-Rad) at 350 V/700 mF in 400 ml of 
electroporation buffer (50 mM, K2HPO4/KH2PO4, 20 mM KAc [pH 7.35], 25 mM MgSO4). 
Untransfected cells (without ectopically expressed FLAG-tagged protein) were processed in 
parallel as a control. Following 3 d of cultivation in DMEM/10% FCS, cells were lysed in 
CoIP buffer, and co-immunoprecipitation experiments using the FLAG antibody were 
performed followed by Western blot detection with anti-FKBP51 and anti-FLAG antibodies 
as described above.
Western Blot Analysis 
Protein extracts were obtained by lysing cells or tissue in lysis buffer containing 62.5 mM 
Tris, 2% sodium dodecyl sulfate and 10% sucrose, completed with protease inhibitor cocktail 
(Sigma, P2714) and phosphatase inhibitor (Roche, 04906837001). After sonication and 
heating for 5 min at 95 °C, samples were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and blotted onto nitrocellulose membranes 
by electrotransfer. Membranes were blocked in Tris-buffered saline, supplemented with 
0.05% Tween (Sigma, P2287) and 5% non-fat milk for 1 h at room temperature. Incubation 
with primary antibodies was carried over night at 4 °C. Subsequently, membranes were 
washed and probed with respective fluorophore- or horseradish peroxidase-conjugated 
secondary antibody for 3-5 h at room temperature. Detectable, immune-reactive bands were 
visualized either by excitation of the respective fluorophore or by using ECL reagent 
(Millipore, WBKL0500). Detection and quantification of band intensities were performed 
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with ChemiDoc MP (BioRad). For quantification of phospho-specific antibody signals, the 
intensity was always referred to the signal intensity of total antibodies. 
Antibodies
For a complete list of primary antibodies, refer to Table 1. Secondary antibodies were donkey 
anti-goat immunoglobulin G, Alexa Flour 488 (Life Technologies, A-11055, 1:7000), anti-
rabbit immunoglobulin G, horseradish peroxidase-linked (Cell Signaling Technologies, 
#7074, 1:10000) and anti-mouse immunoglobulin G, horseradish peroxidase-linked (Cell 
Signaling Technologies, #7076, 1:10000). 
Table 2.4.1 List of all primary antibodies 
Metformin Treatment in MEF Cells 
MEFs derived from 51KO and WT mice were cultivated in a 6-well plate until they reached 
90% confluency. 2 mM metformin hydrochloride (Sigma–Aldrich, St. Louis, USA) was 
subsequently added to the culture media for 48 h. Cells were lysed in and protein extracts 
were prepared and analyzed by Western blot with pTSC2, p4EBP1, and Beclin1 antibodies. 
Quantification of Protein Data 
Protein data were normalized to actin for cell culture experiments and to HSC70 for tissue 
lysates. For normalization actin or HSC70 were detected on the same blot. Data are reported 
as fold change relative to wild-type condition.  
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Animal Studies 
To determine whether FKBP51 affects AMPK-dependent regulation of mTOR signaling in
vivo, metformin, an agonist of AMPK (Zhou et al., 2001), was administered for 6 weeks to 
wild-type (WT) and FKBP51 knockout (51KO) mice. Briefly, 51KO (n = 5) and WT (n = 5) 
mice had ad libitum access to standard lab chow and tap water with metformin. Metformin 
hydrochloride (Enzo Life Sciences, Lörrach, Germany) was chronically administered to mice 
orally through drinking water (2mg/ml, ~300 mg/kg daily). The mice received fresh 
metformin solution twice weekly. Following 6 weeks of metformin treatment, tissues 
(hypothalamus, epididymal (e) white adipose tissue (WAT) inguinal WAT (iWAT), and 
soleus muscle) were collected for protein analyses. 
To determine whether FKBP51 is required for metformin’s glucose-lowering effects, 
metformin was administered for 6 weeks to an independent cohort of WT and 51KO mice in 
a 2x2 experimental design. Briefly, 51KO and WT mice were subdivided into a control and 
metformin treatment group (n=11-13 per group). Mice had ad libitum access to standard lab 
chow and tap water with or without metformin. Metformin was chronically administered to 
mice orally as described above. In the final (6th) week of metformin treatment, fasting blood 
glucose was measured. Body weight, food intake, and fluid intake were measured regularly 
throughout the entire treatment schedule.  
Fasting Blood Glucose 
In order to assess fasting blood glucose, mice were fasted overnight for 14 h. The following 
morning, a tail cut was made, and blood glucose was measured using a handheld Contour XT 
glucometer (Bayer Health Care, Basel, Switzerland).  
Statistical Analysis 
Data were analyzed using IBM SPSS Statistics 18 software (IBM SPSS Statistics, IBM, 
Chicago, IL, USA). Univariate ANOVA with genotype and metformin treatment as fixed 
factors was used to analyze fasting blood glucose. Student’s T-tests were used to assess the 
genotype effect on pTSC2S1387 expression across tissues. Repeated measures ANOVA was 
used for all body weight progression, food intake, and fluid intake data, in which the degrees 
of freedom were corrected for deviance from sphericity (Greenhouse–Geisser) for within-
subjects comparisons. Statistical significance was set at p < 0.05. Data are presented as the 
mean +/- S.E.M. 
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2.4.4. Results
FKBP51 Interacts with AMPK Subunits and TSC2 
Based on the combined observations that FKBP51 interacts with various ser/thr kinases 
(Gassen et al., 2015;Pei et al., 2009;Taipale et al., 2014) and FKBP51 regulates energy 
homeostasis (Chapter 2.3), we initially examined whether FKBP51 interacts with AMPK, the 
principal energy sensor of the cell. The current study demonstrates that FKBP51 binds to 
multiple subunits of AMPK, with the strongest interaction detected between FKBP51 and the 
2 regulatory subunit (Figure 2.4.1a). Furthermore, FKBP51 additionally binds to TSC2 
(Figure 2.4.1b), a direct downstream target of AMPK and the major negative regulator of 
mTOR (Inoki et al., 2003b).  
 
Figure 2.4.1 FKBP51 interacts with AMPK subunits and TSC2 
(a) Immunoprecipitation (IP) of protein complexes was performed using antibodies for each of the 
AMPK subunits (1, 2, 1, 2, 1, 2, and 3). Co-precipitated proteins were visualized by 
Western blotting. FKBP51 co-precipitated with select AMPK subunits (+) but not with others (-). 
(b) HEK cells were transfected with vector control or a FLAG-tagged TSC2-expressing plasmid 
and lysed 72 h later. After immunoprecipitation (IP) of protein complexes using a FLAG antibody, 
input and co-precipitated proteins were visualized by Western blotting. FKBP51 co-precipitated 
with TSC2-FLAG. 
Metformin Action on mTOR Signaling Requires FKBP51 
In order to establish whether the interaction between FKBP51, AMPK subunits, and TSC2 is 
functionally relevant, we sought to examine mTOR signaling in response to metformin, 
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whose mode of action includes the activation of AMPK (Foretz et al., 2014). We assessed 
mTOR activity in MEFs derived either from 51KO or WT mice in order to determine 
whether FKBP51 directs AMPK regulation of mTOR signaling. We found that metformin 
treatment led to an apparent increase in the level of pTSC2S1387, an AMPK-specific 
phosphorylation site within TSC2 in WT MEFs but not in 51KO MEFs (Figure 2.4.2). More 
striking was the FKBP51-dependent metformin effect on downstream signaling. p4EBP1T37/46 
and Beclin1 expression served as readouts for mTOR activity given mTOR directly 
phosphorylates 4EBP1 at Thr- 37 and 46, whereas inhibits autophagy as reflected in the 
levels of the autophagy initiator protein, Beclin1 (Figure 2.4.3) (Wullschleger et al., 2006). In 
particular, Thr-37/46 phosphorylation on 4EBP1 was drastically decreased whereas Beclin1 
expression was drastically increased in WT but not 51KO MEFs from metformin treatment. 
In fact, in 51KO-derived MEFs, the expression of (phospho-) proteins along the mTOR 
signaling pathway was rather uniform between metformin-treated and untreated cells.  
 
Figure 2.4.2 FKBP51 is required for metformin action on mTOR signaling in mouse 
embryonic fibroblasts (MEFs) 
mTOR signaling was examined in MEFs derived from WT or 51KO mice with or without 48 h 
treatment with metformin. Metformin treatment significantly enhanced S1387 phosphorylation of 
TSC2 in WT but not 51KO MEFs. More striking, metformin treatment significantly lowered the 
phosphorylation of T37/46 on 4EBP1 (which are directly phosphorylated by mTOR) exclusively in 
WT MEFs. Metformin-mediated inhibition of mTOR signaling is equally observed downstream of 
mTOR at the level of autophagy (reflected by Beclin1 expression). Again this is exclusively 
observed in WT MEFs. 51KO MEFs are not sensitive to metformin effects at any level examined 
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Figure 2.4.3 Model of FKBP51-dependent regulation of the AMPK-mTOR signaling 
axis
FKBP51 interacts with AMPK and TSC2 to govern downstream mTOR signaling. The interactions 
between FKBP51-AMPK and FKBP51-TSC2 favor AMPK-mediated TSC2 phosphorylation at 
S1387 and thus TSC2 activation. Activated TSC2, within the TSC1-TSC2 complex, inhibits mTOR 
signaling, which is reflected in the phosphorylation states of mTOR direct targets, p70S6K (at 
residue T389) and 4EBP1 (at residues T37 and T46). FKBP51-dependent regulation of the AMPK-
mTOR signaling is equally evident downstream of mTOR at the level of autophagy in which 
inhibition of mTOR ultimately favors autophagic events, as indicated by increased Beclin1 levels, a 
known autophagy initiator protein. 
In order to investigate whether FKBP51 affects AMPK-dependent regulation of mTOR 
signaling in vivo, we stimulated AMPK signaling using metformin in WT and 51KO mice. 
Analysis of pTSC2S1387 in tissues collected from metformin-treated WT and 51KO mice 
revealed that 51KO mice had significantly reduced levels of pTSC2S1387 in comparison to 
WT mice in all tissues examined except for eWAT (eWAT: T8 = 1.540, p = 0.162; iWAT: T8 
= 2.441, p = 0.040; Hypothalamus: T8 = 3.038, p = 0.016; Soleus muscle: T8 = 3.969, p = 
0.004) (Figure 2.4.4). 
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Figure 2.4.4 FKBP51 affects AMPK-dependent regulation of mTOR signaling in vivo 
WT and 51KO mice were treated with metformin in order to stimulate AMPK. pTSC2S1387 was 
assessed as a readout for AMPK-dependent regulation of mTOR. With the exception of epididymal 
white adipose tissue (eWAT), 51KO mice presented significantly reduced pTSC2S1387 expression 
across all tissues examined. Data are presented as the mean +/- s.e.m. +P < 0.05, ++P < 0.01; + 
significant genotype effect. 
Metformin Glucose-Lowering Action is Independent of FKBP51 
Based on our findings suggesting that FKBP51 is required for metformin action on mTOR 
signaling, we sought to examine the efficacy of metformin treatment in 51KO and WT mice. 
Metformin had no effect on body weight gain, food intake, or fluid intake measured over the 
entire treatment period, independent of genotype (Figure 2.4.5a – c). Nevertheless, a 
significant Time x Genotype interaction revealed that 51KO mice presented slower body 
weight gain compared to WT over the 6 week experimental period (Time x Genotype: F(1, 
113.1) = 2.941, p = 0.044). By contrast, metformin treatment significantly decreased fasting 
glucose (Treatment: F(1,41) = 5.101, p = 0.029) (Figure 2.4.5d). The effect of metformin on 
fasting glucose was independent of genotype.  
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Figure 2.4.5 Metformin lowers fasting blood glucose independent of genotype 
Oral administration of metformin for 6 weeks to WT and 51 KO mice had no effect on body weight 
gain (a), food intake (b) or fluid intake (c), independent of genotype. 51KO mice nevertheless 
presented slower body weight gain compared to WT mice. Finally, metformin treatment 
significantly lowered fasting blood glucose, regardless of genotype (d). Data are presented as the 
mean +/- s.e.m. #P < 0.05; # significant metformin treatment effect. 
2.4.5. Discussion 
The results from the current study demonstrate that FKBP51 is important for AMPK-
dependent regulation of mTOR signaling. We have demonstrated that FKBP51 is found in 
complex with AMPK and TSC2. Interestingly this interaction appears to have functional 
consequences. Specifically, MEFs lacking FKBP51 were unresponsive to metformin-
mediated regulation of mTOR signaling. In fact, the FKBP51-dependent effects of metformin 
were evident all the way down to the level of autophagy. In line with these findings, 
metformin-treated 51KO mice presented less activation of TSC2 (pTSC2S1387), the principal 
negative regulator of mTOR, and consequently increased activation of mTORC signaling 
(assessed from levels of phosphorylated p70 ribosomal S6 kinase (pp70S6K) at thr-389 
(pp70S6KT389)) compared to metformin-treated WT mice. Nevertheless, chronic metformin 
treatment reduced fasting blood glucose in both WT and 51KO mice, which suggests that 
metformin is still able to mediate its glucose-lowering effects independent of FKBP51. Taken 
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together we identify FKBP51 as a novel constituent of the AMPK heterocomplex, a novel 
regulator of the AMPK-mTOR signaling axis, and an important determinant in the cellular 
response to the widely used anti-diabetic drug metformin. 
AMPK is a heterotrimeric complex, in which all three subunits are essential for significant 
kinase activity (Dyck et al., 1996). In mammals several isoforms for each subunit exist. In 
particular, there are two -subunits, three -subunits, and two -subunits (1, 2, 1, 2, 3, 
1, and 2) (Krishan et al., 2015). Each isoform shows tissue-specific expression patterns. 
Importantly, the various isoforms present different substrate preferences, suggesting that 
distinct isoforms may confer distinct functional properties (Sinnett and Brenman, 
2014;Woods et al., 1996). Interestingly, our co-immunoprecipitation experiments revealed 
that FKBP51 preferentially binds certain AMPK subunits. For example, FKBP51 showed no 
binding to 1 or 3 subunits. These results support the literature that has found substrate 
preference between isoforms (Sinnett and Brenman, 2014;Woods et al., 1996). Importantly, 
the specificity of interaction between FKBP51 and distinct AMPK isoforms suggests that 
FKBP51 is able to modulate specific AMPK signaling pathways while leaving others 
unperturbed. If we consider the  regulatory subunit, FKBP51 strongly binds 2, whereas 
does not bind the 1 subunit. Interestingly, whereas 1 is highly expressed in liver, 2 is 
highly expressed in skeletal muscle (Thornton et al., 1998). This suggests that FKBP51 may 
be able to modulate muscle-specific AMPK signaling cascades, whereas leave liver-specific 
AMPK signaling unperturbed. In support of the current hypothesis, FKBP51 is highly 
expressed in mouse skeletal muscle, but is not expressed in mouse liver (unpublished data). 
LKB1 is recognized as a key upstream AMPK-activating kinase. As a ser/thr protein kinase, 
LKB1 phosphorylates AMPK at Thr-172, which in turn phosphorylates numerous substrates 
regulating diverse metabolic processes. A previous study identified a strong interaction 
between LKB1 and FKBP51 (Taipale et al., 2014), but no further investigation was 
performed. Here we show that FKBP51 exists in complex with AMPK and downstream 
effectors of AMPK, thereby determining the signaling fate of AMPK activation. Given the 
multiple downstream effectors which AMPK targets, the ability to direct AMPK action 
towards select targets and to furthermore organize specific protein complexes (including both 
upstream regulators and downstream effectors) has significant implications. It is important to 
establish whether additional downstream effectors of AMPK are also interacting partners of 
FKBP51. Regardless, the past study identifying LKB1 as an interaction partner of FKBP51 
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and the current study identifying AMPK and TSC2 as interaction partners of FKBP51, 
indicate an important regulatory role for FKBP51 along this signaling axis. 
FKBP51 gene expression is highly responsive to the environment. For example, FKBP5 
expression is responsive to stress, dexamethasone administration, as well as to the dietary 
condition (Balsevich et al., 2014;Guidotti et al., 2013;Pereira et al., 2014b;Scharf et al., 
2011;Vermeer et al., 2003). In this regard, it is tempting to speculate that FKBP51 may 
facilitate spatio-temporal signaling cascades in response to environmental challenges in order 
to re-establish homeostasis. Indeed the environmental context is also very important for 
AMPK, which is recognized as the cellular sensor of energy status. Taken together, we 
hypothesize that FKBP51 governs downstream AMPK targets in response to specific 
environmental stimuli. Future work should address to what extent the FKBP51-dependent 
regulation of AMPK relies on the environmental context. 
Metformin is the first-line oral treatment for patients with type 2 diabetes. Although its mode 
of action is not entirely understood, metformin is known to activate AMPK, and metformin-
induced AMPK activation is an essential entity to its therapeutic effects (Foretz et al., 2014). 
As an antidiabetic agent, metformin is known to combat hyperglycemia without inducing 
hypoglycemia or weight gain. Therefore we investigated whether the glucose-lowering 
capacity of metformin depends on FKBP51. We observed no effect of metformin on body 
weight gain or food intake. However, we observed the expected metformin-mediated 
reduction in fasting glucose. Interestingly, this effect was independent of the FKBP51 
genotype, suggesting that metformin is able to act independent of FKBP51 to regulate 
glucose homeostasis. Based on our findings that FKBP51 does not regulate AMPK per se, but 
rather facilitates the interaction between AMPK and its downstream target TSC2 to 
ultimately govern mTOR signaling, it is not surprising that metformin is still able to reduce 
fasting glucose levels. In fact the ability of metformin to counteract hyperglycemia has been 
largely ascribed to non-mTOR signaling pathways (Foretz et al., 2014). Nevertheless, 
FKBP51-directed AMPK regulation of mTOR signaling is highly relevant and warrants 
further investigation into its impact on (patho-) physiological outcomes.  
Limitations 
The current study is largely observational and serves as a starting point for continued analysis 
of FKBP51-dependent regulation of the AMPK-mTOR signaling axis. In particular, 
quantification analyses of AMPK-mTOR signaling are required with additional controls to 
show the specificity of metformin action on the AMPK-mTOR signaling axis and not simply 
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on all downstream targets. Another limitation is the design of the AMPK stimulation in WT 
and 51KO mice using metformin in order to assess the AMPK-mTOR signaling axis. 
Specifically, we did not include a non-stimulated (metformin-free) condition. Studies are 
currently underway in order to overcome these limitations. Nevertheless the current study 
warrants further investigation into the novel FKBP51-dependent regulation of the AMPK-
mTOR signaling axis. 
Conclusion
In the past few years, studies have identified a number of novel interacting partners of 
FKBP51. In this sense, FKBP51 acts as a scaffolding protein to facilitate the interaction 
between signaling molecules and their regulators in order to concentrate and thus functionally 
regulate such molecules. The current study establishes a novel interaction between FKBP51, 
AMPK, and the regulator of mTOR, TSC2. Furthermore, it was already known that an 
upstream regulator of AMPK, LKB1 is one of the strongest interacting partners of FKBP51. 
Taken together, FKBP51 is in a prime location to regulate AMPK signalling, both upstream 
and downstream, through direct protein-protein interactions.  
 
Research Articles
 
100 
 
2.5. FKBP51 Acts in the Hypothalamus to Regulate Body 
Weight
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2.5.1. Abstract
FK506 binding protein 51 (FKBP51, encoded by the FKBP5 gene) has been identified as a 
susceptibility gene for stress-related disorders. We and others have recently found a novel 
role for FKBP51 in whole body energy homeostasis. However, the broad expression profile 
of FKBP51 across peripheral tissues and the central nervous system has hampered attempts to 
define the exact mode of action in which FKBP51 contributes to energy homeostasis. In order 
to isolate the hypothalamic action of FKBP51 on metabolic regulation, we overexpressed 
FKBP51 within the hypothalamus using adeno-associated viral vector-mediated Fkbp5 gene 
transfer. FKBP51 overexpression within the hypothalamus resulted in decreased body weight 
gain as early as 3 weeks post-surgery compared to control viral-injected mice. The reduction 
in body weight gain arising from hypothalamic FKBP51 overexpression persisted for an 
additional 6 weeks until the end of the experiment under both chow and high fat diet 
conditions. The lowered body weight phenotype observed in hypothalamic FKBP51-
overxpressing mice was accompanied by hypophagia. Double in situ hybridization revealed 
that Fkbp5 mRNA is co-expressed in both Pomc- and Npy-containing neurons, suggesting 
possibly multiple sites of action for FKBP51 across the hypothalamus. Collectively, the 
current findings implicate FKBP51 action within the hypothalamus as a determinant of body 
weight and food intake, in which NPY- and POMC-containing neurons are both plausible 
sites of FKBP51 action. 
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2.5.2. Introduction 
Obesity is a major health concern, and is a recognized risk factor for cardiovascular disease, 
atherosclerosis, and type 2 diabetes (Friedman, 2009). Although significant progress has been 
made to elucidate biological mechanisms of energy balance and related diseases, its entirety 
is poorly understood. Body weight regulation is a polygenic trait, and involves the interplay 
between environmental and genetic factors (Barsh et al., 2000). Identification of novel 
genetic targets provides a means to understand novel regulatory mechanisms in energy 
homeostasis and new therapeutic potentials.  
FK506 binding protein (FKBP51, encoded by the FKBP5 gene) is a member of the 
immunophilin protein family, and was first identified in HeLa cells as a component of the 
Hsp90-progesterone complex (Smith et al., 1993). Since then, additional functions of 
FKBP51 have been identified and include the regulation of steroid hormone receptors, 
distinct kinases and transcription factors, the microtubule-associated protein Tau, as well as 
autophagic events (Gassen et al., 2014;Jiang et al., 2008;Jinwal et al., 2010;Pei et al., 
2009;Storer et al., 2011). Through its pleiotropic regulatory properties, FKBP51 has been 
implicated in the etiology of stress-related psychiatric disorders, various cancers, and 
neurodegenerative disorders (Schmidt et al., 2012). Convincing evidence suggests that 
tissue/cell-type specific expression may be associated with specialized physiological roles for 
FKBP51. For example, FKBP51 is upregulated in certain cancer types, namely melanoma, 
brain cancers, prostate cancer, lymphoma, and head and neck cancer, whereas downregulated 
in other cancer types, including pancreatic cancer, colon cancer, and testicular cancer (Li et 
al., 2011). The differential FKBP51 expression profile amongst various cancer types has been 
attributed to tissue-specific FKBP51-dependent regulation of distinct signaling pathways. 
Recently, we and others have furthermore demonstrated a novel role for FKBP51 in 
metabolic regulation (unpublished data, refer to Chapter 2.3, (Pereira et al., 2014b)). 
Specifically, we have shown that genetic ablation of FKBP51 in mice protects against diet-
induced obesity and systemic glucose intolerance (unpublished data, refer to Chapter 2.3). 
Nevertheless, the broad expression profile of FKBP51 across various tissues (Su et al., 2004) 
has hindered the ability to define the exact mode of action in which FKBP51 contributes to 
disease etiology. Taken together, FKBP51 has several potential sites of regulation within the 
context of whole body energy metabolism.  
Regulation of whole body energy homeostasis requires the concerted actions of multiple 
tissues. There is significant crosstalk between peripheral organs, which convey peripheral 
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information regarding the energy status of the body, and the central nervous system, which is 
responsible for sensing and integrating these peripheral signals, in order to mount a response 
(Dietrich and Horvath, 2013).Within the central nervous system, the hypothalamus contains 
cell populations intimately involved in the maintenance of energy intake and energy 
expenditure and consequently the regulation of body weight (Gao and Horvath, 2007). In 
more detail, the hypothalamus is comprised of several nuclei, including the arcuate nucleus 
(ARC), the paraventricular nucleus (PVN), the ventromedial hypothalamic nucleus (VMH), 
and the dorsomedial hypothalamic nucleus (DMH) which have all been implicated in the 
regulation of body weight (Gao and Horvath, 2007). Perhaps the most recognized network 
involved in body weight regulation is the melanocortin system, consisting of two subsets of 
neurons, POMC- and NPY- containing neurons within the arcuate nucleus and their 
projections. Both sets of neurons are able to respond to peripheral cues which reflect energy 
status. For example, leptin, which circulates at levels proportional to the degree of adiposity, 
activates POMC neurons whereas inhibits NPY activity. Interestingly, POMC and NPY have 
opposing effects on food intake and body weight regulation, whereby POMC is a recognized 
anorexigenic neuropeptide whereas NPY is rather an orexigenic neuropeptide. Therefore, 
given the fundamental role of the hypothalamus in energy homeostasis, we sought to identify 
the specific role of hypothalamic FKBP51 on body weight regulation. 
2.5.3. Methods
Animals & Animal Housing 
Male C57BL/6N mice between 3-4 months were used (Charles River Laboratories, 
Maastricht, Netherlands). Mice were maintained on a 12:12hr light/dark cycle, with 
controlled temperature (22 +/- 2°C) and humidity (55+/- 5%) conditions. Mice had ad libitum 
access to water and standard lab chow, unless otherwise specified. The experiments were 
carried out in accordance with the European Communities' Council Directive 2010/63/EU. 
The protocols were approved by the committee for the Care and Use of Laboratory animals 
of the Government of Upper Bavaria, Germany. 
Experimental Design 
To assess the contribution of hypothalamic FKBP51 on energy homeostasis, adeno-
associated viral (AAV) vector-mediated Fkbp5 gene transfer into the hypothalamus was 
performed (Figure 2.5.1a). Mice were initially singly-housed one week prior to the 
experimental onset. Bilateral microinjections targeting the hypothalamus were performed 
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from experiment day 1 to experiment day 4 for AAV vector delivery of Fkbp5 or empty 
control. Mice selected for AAV vector delivery of Fkbp5 overexpression (51OE, n = 28) or 
empty control (Empty, n = 26) were counterbalanced for body weight. Mice were allowed to 
recover for 4 weeks following the surgeries with minimal disturbance. Following the 4-week 
recovery period, mice from each genotype group (51OE and Control) were divided into 
chow-fed and high fat diet (HFD)-fed groups, balanced by body weight. For an additional 6 
weeks, mice received ad libitum access to either HFD (58% kcal from fat, D12331, Research 
Diets, Inc., New Brunswick, NJ, USA) or control chow diet (10.5% kcal from fat,D12329). 
Food intake and body weight were carefully monitored over the 6 week dietary period. In the 
final week of the experiment, mice were assessed for locomotor activity in the open field. 
Micro-Injections 
AAV vector-mediated overexpression of FKBP51 was performed using an adeno-associated 
bicistronic AAV1/2 vector as previously described (Schmidt et al., 2011). AAV vectors were 
designed and obtained by GeneDetect (Auckland, New Zealand). An injection volume of 0.5 
μl was used to deliver AAV vectors expressing either the human FKBP51 cDNA sequence 
(CAG-HA-tagged-FKBP51-WPRE-BGH-polyA expression cassette; titer: 1.2x1012 GP/ml) 
or an empty vector construct (CAG-Null/Empty-WPRE-BGH-polyA). For bilateral 
microinjections into the hypothalamus, mice were anesthetized with isoflurane and fixed in a 
stereotaxic frame in order to target the following coordinates relative to Bregma: posterior 1.5 
mm; 0.5 mm lateral; 5.2 mm ventral. Injections were carried out using glass capillaries with a 
tip resistance of 2–4M	 over 10 min (0.05 l/min). Successful AAV vector targeting was 
later confirmed on brain sections by in situ hybridization.  
Fasting Blood Glucose Levels 
Mice were fasted overnight (14 h). Blood glucose levels were subsequently measured on 
blood collected by tail cut using a handheld Contour XT glucometer (Bayer Health Care, 
Basel, Switzerland).  
Open Field 
In order to assess locomotor activity, mice were placed in one corner of a 50 cm x 50 cm x 50 
cm arena under dim light (15 Lux) conditions. Thirty-minute trials were video-recorded by an 
overhead camera. Tests were recorded using a video-tracking system (Anymaze 4.20; 
Stoelting). All behavioral equipment was cleaned with water at the beginning of testing and 
between each animal. Total distance travelled was taken as a measure of locomotor activity. 
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Tissue Collection 
On the day of sacrifice, mice were deeply anesthetized with isoflurane. Blood was collected 
by cardiac puncture. Immediately thereafter, mice were transcardially perfused with 0.1M 
phosphate-buffered saline (PBS) followed by 4% (v/v) paraformaldehyde (PFA) fixative in 
PBS. Brains were rapidly removed and post-fixed in 4% PFA overnight at 4°C. The 
following day, post-fixed brains were transferred to a cryoprotectant solution (30% (w/v) 
sucrose in 0.1M PBS) for an additional overnight incubation at 4°C. Brains were stored at -
80°C until used. Liver, epididymal adipose tissue, and inguinal adipose tissue were also 
collected, immediately frozen on dry ice, and stored at -80°C.  
Hormone Quantification 
Blood samples were collected in EDTA-coated tubes and stored on ice until processed. 
Plasma was separated from collected blood by centrifugation at 6000 g at 4°C for 15 min. 
Plasma insulin and leptin levels were determined using a mouse metabolic magnetic bead 
panel (Millipore Corp. Billerica, Massachusetts; sensitivity: insulin 14pg/ml; leptin 19pg/ml). 
Corticosterone levels were determined using a commercially available RIA kit (MP 
Biomedicals, Inc., Solon, OH, USA; sensitivity 12.5 ng/ml).  
In Situ Hybridization (ISH) 
ISH was performed on coronal brain sections (25 μm thick) that were cut on a cryostat as a 
1:6 series as previously described (Schmidt et al., 2007). Specifically, a 35S-UTP-labeled 
antisense cRNA probe for Fkbp5 (Forward primer: 5’-CTTGGACCACGCTATGGTTT; 
Reverse primer: 5’- ATTGACTGCCAACACCTT) was used. For signal detection, slides 
were exposed to a Kodak Biomax MR film (Eastman Kodak Co). Autoradiographic densities 
were quantified using the NIH ImageJ Software (NIH, Bethesda, MD, USA) to both validate 
and quantify hypothalamic Fkbp5 overexpression.  
Double In Situ Hybridization (DISH) 
In a separate cohort of test-naïve C57BL/6N male mice, coronal brain sections were 
cryosectioned at 20μm thickness and directly thaw mounted onto Super Frost Plus Slides. For 
the co-localization of Fkbp5 mRNA with Pomc and Npy, 35S UTP-labelled Fkbp5 riboprobe 
was used with either a digoxigenin (DIG)-labelled Pomc riboprobe or DIG-labelled Npy
riboprobe. The antisense riboprobes were transcribed from a linear plasmid for Fkbp5 
(forward 
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primer: 5’- CTT GGA CCA CGC TAT GGT TT -3’; reverse primer: 5’-GGA TTG ACT 
GCC AAC ACC TT-3’), Pomc , (forward primer: 5’- TTA CGG TGG CTT CAT GAC CT – 
3’; reverser primer: 5’ – AGA GCC GAC TGT GAA ATC TGA – 3’), and Npy (forward 
primer: 5’ – AGG AAA GCA CAG AAA ACG CC-3’; reverse primer: 5’- AAC AAC AAG 
GGA AAT GGG GC - 3’). Double in situ hybridization (DISH) was performed as previously 
described (Refojo et al., 2011). Briefly, sections were fixed in 4 % PFA. After several 
washing steps, endogenous peroxidase was quenched in 1% H202. Background was reduced 
in 0.2 M HCl, followed by 2 additional washing steps (1 x PBS). The slides were acetylated 
in 0.1 M triethanolamine, washed (1 x PBS) and dehydrated through increasing 
concentrations of ethanol. Tissue sections were saturated with 90 l of hybridization buffer 
containing approximately 50,000 cpm/μl 35S-labelled riboprobe and 0.2μg/ml DIG-labelled 
riboprobe. Brain sections were cover-slipped and incubated overnight at 55 °C. The 
following day, coverslips were removed and sections were washed several times in 
decreasing concentrations of SSC/formamide buffers under stringent temperature settings. 
After SSC washes, sections were treated with RNAse A in 1 x NTE at 37°C and washed in 1x 
NTE/0.05% Tween20 (2x times) followed by a blocking step in 4% BSA for 1 hour. After 
additional washing steps, sections were blocked in NEN-TNB for 30 min. In a final step, 
slides were incubated with Roche’s anti-DIG (FAB) (1:400, Roche Molecular Diagnostics) at 
4°C overnight. On the last day, sections were washed several times in TNT at 30°C followed 
by a signal amplification step in which sections were incubated for 15 min in tyramide-biotin. 
Thereafter, additional washing steps were performed (Roche washing buffer, Roche 
Molecular Diagnostics). Sections were then incubated for 1 h with Roche streptavidin-AP 
(1:400, Roche Molecular Diagnostics). Sections were washed in Roche washing buffer and 
were subsequently prepared for Vector red staining in 100mM Tris/HCL (Vector 
Laboratories, Burlingame, CA, USA). Slides were immersed in Vector red solution under 
unlit conditions for 15-30 min depending on staining. When staining was sufficient, the 
reaction was stopped in 1 x PBS followed by a fixation step in 2.5% glutaraldehyde. Finally, 
sections were washed in 0.1 x SSC and dehydrated in a graded series of ethanol solutions (30, 
50, 70, and 96%). 
Statistical Analysis 
Data were analyzed using IBM SPSS Statistics 18 software (IBM SPSS Statistics, IBM, 
Chicago, IL, USA). For the comparison of two groups, independent Student’s t-tests were 
used. A one-way repeated measures ANOVA was used for longitudinal analysis of body 
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weight progression, in which the degrees of freedom were corrected for deviance from 
sphericity (Greenhouse–Geisser) for within-subjects comparisons. A Bonferroni post hoc test 
was used for ANOVA tests to determine statistical significance between individual groups. 
Finally, correlations were analyzed with the Pearson product-moment test. Statistical 
significance was set at p < 0.05 and a statistical trend at p < 0.1. Data are presented as the 
mean +/- S.E.M. 
2.5.4. Results
Validation of AAV Vector-Mediated Overexpression of FKBP51 in the Hypothalamus 
Viral-mediated gene transfer to the hypothalamus was used to selectively overexpress 
FKBP51. In situ hybridization of coronal hypothalamic sections was later used to quantify the 
level of overexpression across hypothalamic nuclei and was additionally used to exclude 
mice who presented off-target injection sites. Mice that were not infected bilaterally in the 
hypothalamus were excluded from all analyses. In total, 13 empty and 9 51OE mice under 
chow diet conditions and 11 empty and 14 51OE mice under HFD were used for further 
analyses. AAV vector-mediated delivery of FKBP51 resulted in a significant increase in 
FKBP51 mRNA expression within the PVN (T20.4 = -19.063, p < 0.001), ARC (T23.5 = -
7.594, p < 0.001), VMH (T24.0 = -18.171, p < 0.001), and DMH (T22.3 = -17.782, p < 0.001) 
compared to empty control animals (Figure 2.5.1b). 
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Figure 2.5.1 Experimental design and validation of hypothalamic Fkbp5 
overexpression 
(A) Experimental time course. Brain-site specific microinjections were performed on 10-week -old 
C57BL/6 male mice for the delivery of Fkbp5 or an empty control construct to the hypothalamus. 
Following 4 weeks of recovery, mice from each genotype group were divided into a dietary group 
and were subsequently exposed to either chow diet or HFD for an additional 6 weeks. Metabolic 
readouts were carried out in the final week of the dietary regime. (B) Representative 
autoradiographs of viral Fkbp5 mRNA expression in the PVN, ARC, VMH, and DMH of the 
hypothalamus and quantification of Fkbp5 mRNA levels across the PVN, ARC, VMH, and DMH.  
+++P < 0.001; + significant viral effect. 
Effects of Hypothalamic FKBP51 Overexpression on Body Weight and Food Intake 
Body weight was monitored regularly during the recovery period following the 
microinjections and thereafter during the 6-week dietary period. At the time of 
microinjections, mice were divided into viral groups counterbalanced for body weight, and 
therefore on the day of surgery there was no difference in body weight between the 2 viral 
expression groups (Figure 2.5.2a). A one-way repeated measures ANOVA performed for 
body weight gain from 1 week post-surgery to 4 weeks post-surgery revealed that as early as 
3 weeks post-surgery, FKBP51 overexpression led to a significant reduction in body weight 
gain (Time x Virus: F(1, 97.2) = 15.741, p < 0.001; Virus: F(1, 45) = 4.698, p = 0.036) 
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(Figure 2.5.2b). Following 4 weeks recovery, mice of each viral expression group were 
further divided into chow-fed and HFD-fed mice. Mice fed either chow or HFD, presented 
reduced body weight gain on account of hypothalamic FKBP51 overexpression (Chow: Time 
x Virus: F(1, 46.9) = 4.483, p = 0.011, Virus: F(1, 19) = 8.343, p = 0.009; HFD: Time x 
Virus: F(1, 35.9) = 6.195, p = 0.008, Virus: F(1, 23) = 9.040, p = 0.006) (Figure 2.5.2c). 
Accordingly, the final body weight assessed at the end of the experiment was significantly 
lower in 51OE mice compared to empty control mice, although consumption of a HFD 
significantly increased final body weight, independent of genotype (Virus: F(1, 42) = 15.400, 
p < 0.001; Diet: F(1, 42) = 36.038, p < 0.001). This was also observed using the Pearson 
product-moment test to assess the relationship between Fkbp5 expression and body weight. 
The Pearson product-moment test revealed negative associations between final body weight 
and Fkbp5 expression within the PVN (Chow: r = -0.504, p = 0.028; HFD: r = -0.485, p = 
0.026), the ARC (Chow: r = -0.267, p = 0.255; HFD: r = -0.523, p = 0.010), the VMH 
(Chow: r = -0.522, p = 0.018; HFD: r = -0.671, p < 0.001), and the DMH (Chow: r = -0.537, 
p = 0.015; HFD: r = -0.622, p = 0.002) (Figure 2.5.2d). Additionally, FKBP51 hypothalamic 
overexpression significantly reduced caloric intake (Virus: F(1, 43) = 6.022, p = 0.018), 
whereas HFD exposure significantly increased caloric intake (Diet: F(1, 43) = 72.832, p < 
0.001) (Figure 2.5.2e). In fact, in chow-fed animals the reduced body weight phenotype 
arising from hypothalamic FKBP51 overexpression is explained by the significant reduction 
in caloric intake as shown by ANCOVA for final body weight using caloric intake as a 
covariate (caloric intake: F(1, 18) = 13.637, p = 0.002; Virus: F(1, 18) = 1.789, p = 0.198). 
However, in HFD-fed mice additional factors besides only caloric intake contribute to the 
effects of hypothalamic FKBP51 overexpression on body weight regulation (caloric intake: 
F(1, 22) = 7.005, p = 0.015; Virus: F(1, 22) = 6.830, p = 0.016). Finally, our data indicate that 
changes in locomotor activity do not underlie the lean phenotype given that hypothalamic 
overexpression of FKBP51 had no effect on locomotor activity examined in the open field 
over 30 min in either chow-fed mice or HFD-fed mice (Figure 2.5.2f).  
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Figure 2.5.2 Effects of hypothalamic FKBP51 overexpression on body weight and food 
intake 
(A) At the onset of AAV vector-mediated FKBP51 overexpression within the hypothalamus, there 
was no difference in body weight between groups. (B) Hypothalamic overexpression of FKBP51 
decreased the progression of body weight, which was already evident during the 4-week recovery 
stage. (C) 51OE mice presented reduced body weight throughout the entire dietary regime under 
both chow and HFD conditions, which is reflected in the body weight at the experimental endpoint. 
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(D) Correlational analyses between the final body weight and Fkbp5 expression across 
hypothalamic nuclei (PVN, ARC, VMH, and DMH) revealed strong negative correlations between 
Fkbp5 expression levels and final body weight. (E) A reduction in food intake (kcal/day) was 
observed in 51OE mice, whereas both genotype groups presented HFD-mediated increased food 
intake. (F) Examination of locomotor activity in the open field over a 30 min period revealed no 
effect of either genotype or diet. +P < 0.05, ++P < 0.01, +++P <0.001, ###P < 0.001; + significant 
viral effect; # significant diet effect. Correlations were analyzed with the Pearson product-moment 
test with statistical significance set at p < 0.05. 
Effects of Hypothalamic FKBP51 Overexpression on Circulating Levels of Glucose and 
Signaling Hormones 
In order to examine whether AAV viral-mediated hypothalamic FKBP51 overexpression 
impacts fasting blood glucose, we fasted the mice for 14 h and then collected blood by tail 
cut. Overall, FKBP51 overexpression lowered fasting blood glucose (Virus: F(1, 43) = 4.702, 
p = 0.036) (Figure 2.5.3a). Likewise, hypothalamic overexpression of FKBP51 lowered 
circulating leptin levels (Virus: F(1, 41) = 4.233, p = 0.046) (Figure 2.5.3b). In addition, 
HFD-fed mice presented elevated levels of leptin compared to chow-fed counterparts (Diet: 
F(1, 41) = 7.079, p = 0.011). Interestingly, although there was a significant diet effect on 
circulating insulin levels (Diet: F(1, 41) = 11.971, p = 0.001), we observed no effect of 
genotype (Figure 2.5.3c). Finally, we also measured corticosterone levels, and we found that 
both HFD (Diet: F(1, 40) = 4.810, p = 0.034) and hypothalamic FKBP51 overexpression 
(Virus: F(1,40) = 12.789, p = 0.001) increased circulating corticosterone levels (Figure 
2.5.3d). The Pearson product-moment test to assess the relationship between Fkbp5 
expression and corticosterone also revealed strong tendencies for positive associations 
between corticosterone and Fkbp5 expression within the PVN (Chow: r = 0.418, p = 0.075; 
HFD: r = 0.446, p = 0.055), the ARC (Chow: r = 0.561, p = 0.010; HFD: r = 0.239, p = 
0.296), the VMH (Chow: r = 0.397, p = 0.083; HFD: r = 0.400, p = 0.072), and the DMH 
(Chow: r = 0.375, p = 0.103; HFD: r = 0.479, p = 0.028) (Figure 2.5.3e). 
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Figure 2.5.3 Effects on hypothalamic FKBP51 overexpression on fasting glucose and 
circulating hormone levels 
(A) 14h-fasting glucose was significantly lowered on account of hypothalamic overexpression of 
FKBP51. (B) Circulating leptin levels were found to be decreased by hypothalamic overexpression 
of FKBP51, whereas were found to be increased by HFD exposure. (C) Circulating levels of 
insulin were insensitive to hypothalamic FKBP51 overexpression, but were nevertheless 
significantly increased by HFD exposure. (D) Morning corticosterone was significantly increased 
by both hypothalamic FKBP51 overexpression and HFD exposure. (E) Correlational analyses 
between plasma corticosterone and Fkbp5 expression across hypothalamic nuclei (PVN, ARC, 
VMH, and DMH) revealed positive correlations between Fkbp5 expression levels and plasma 
corticosterone. +P < 0.05, +++P <0.001, #P < 0.05, ###P < 0.001; + significant viral effect; # 
significant diet effect. Correlations were analyzed with the Pearson product-moment test with 
statistical significance set at p < 0.05 and a statistical trend at p < 0.1. 
 
Cellular FKBP51 Expression in the Arcuate Nucleus 
The cellular distribution of FKBP51 across the hypothalamus, and specifically within the 
ARC, is unknown. For this purpose we performed double in situ hybridization in order to co-
localize the mRNA of Fkbp5 with either Npy or Pomc mRNA. As expected, Pomc expression 
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was detected within the ARC. Fkbp5 expression was dispersedly distributed across the 
hypothalamus. Importantly, our results demonstrated that Fkbp5 mRNA co-localized with 
Pomc within the ARC (Figure 2.5.4). Likewise, Npy expression was detected primarily in the 
ARC, but was also detected to a degree in the VMH. Within the ARC, we found that Fkbp5 
largely co-localized with Npy. Interestingly, although the greater extent of Npy-expressing 
neurons co-expressed Fkbp5, there was a sub-population of Npy-positive cells that did not co-
express Fkbp5 (Figure 2.5.5).  
 
Figure 2.5.4 Fkbp5 is co-expressed with pomc-containing neurons 
(A – C) Representative bright-field photomicrographs of brain sections derived from C57BL/6 
mice showing double in situ hybridization of Fkbp5 mRNA (silver grains) and pomc mRNA (red 
staining) within the ARC. Dashed lines delineate the VMH and ARC nuclei within the 
hypothalamus. Black arrows indicate cells co-expressing Fkbp5 and Pomc, whereas white arrows 
indicate cells only expressing Fkbp5. 
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Figure 2.5.5 Fkbp5 is co-expressed with npy-containing neurons 
(A – C) Representative bright-field photomicrographs of brain sections derived from C57BL/6 
mice showing double in situ hybridization of Fkbp5 mRNA (silver grains) and npy mRNA (red 
staining) within the ARC. Dashed lines delineate the DMH and ARC nuclei within the 
hypothalamus. Black arrows indicate cells co-expressing Fkbp5 and npy, whereas grey arrows 
indicate cells only expressing Npy, whereas white arrow indicate cells only expressing Fkbp5. 
 
2.5.5. Discussion 
The major finding of the current study was that FKBP51 overexpression within the 
hypothalamus reduces body weight gain and food intake, independent of dietary context. In 
addition, 51OE mice presented lower levels of circulating leptin, whereas elevated levels of 
circulating morning corticosterone. We found that Fkbp5 is expressed in two types of 
peptide-secreting neurons within the ARC, Npy-expressing and Pomc-expressing neurons, 
which are critical regulators of feeding. In conclusion, the current findings implicate FKBP51 
action within the hypothalamus as a determinant of body weight and food intake. Future 
studies will be able to build on these findings, to decipher the exact role of FKBP51 within 
subpopulations of hypothalamic neurons on whole body energy homeostasis. 
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We hypothesized that hypothalamic overexpression of FKBP51 would lead to obesity based 
on our previous (unpublished) data that total loss of FKBP51 protects against HFD-induced 
obesity (Chapter 2.3). To our surprise, hypothalamic FKBP51 overexpression paradoxically 
led to a slower progression of body weight gain. Nevertheless, unlike FKBP51 knockout 
(51KO) mice, 51OE mice were not protected from HFD-induced weight gain. Instead, under 
both chow and HFD conditions, 51OE mice presented reduced body weight over the entire 6 
week dietary regimen. Furthermore, 51OE mice under both chow and HFD conditions 
presented reduced food intake, suggesting that FKBP51-mediated hypophagia partly 
underlies the body weight phenotype. ANCOVA using caloric intake as a covariate revealed 
that this is indeed the case in chow-fed mice, since the effect of hypothalamic overexpression 
on final body weight is lost when caloric intake is accounted for. However, in HFD-fed mice 
hypothalamic FKBP51 overexpression remained significant even after controlling for caloric 
intake suggesting that additional mechanisms underlie the hypothalamic FKBP51-mediated 
effects on body weight regulation under HFD conditions. In addition to the body weight 
phenotype in 51OE mice, hypothalamic FKBP51 overexpression furthermore reduced 
circulating levels of leptin. This agrees with the lower body weight of 51OE mice, given that 
leptin circulates at concentrations proportional to body fat mass (Considine et al., 1996). In 
summary, although at first glance the effects of hypothalamic 51OE appear paradoxical in 
view of the 51KO mouse experiments (in which both 51KO and hypothalamic 51OE induced 
weight loss), a more detailed analysis revealed different underlying mechanisms. 
Specifically, whereas hypothalamic FKBP51 overexpression had a strong effect on food 
intake, total loss of FKBP51 had no effect on food intake but rather had a strong effect on 
energy expenditure and glucose metabolism. Examination of circulating insulin levels 
revealed a strong effect of HFD exposure, but no effect of genotype. Interestingly, genetic 
ablation of FKBP51 in mice also has no effect on circulating concentrations of insulin, 
despite an impressive effect on body weight control (unpublished data). Collectively, such 
data imply that FKBP51 is not involved in the regulation of insulin secretion at the level of 
the pancreas. Despite no effect on insulin secretion, hypothalamic FKBP51 overexpression 
was found to reduce fasting blood glucose levels, suggesting that other mechanisms 
regulating whole body glucose homeostasis are influenced by FKBP51 hypothalamic action. 
Additional studies should examine fasting insulin levels and glucose-stimulated insulin levels 
in hypothalamic 51OE mice in order to reinforce the current findings.  
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Evaluation of circulating morning corticosterone levels revealed a robust genotype effect in 
which hypothalamic FKBP51 overexpression significantly increased corticosterone levels. 
This is in strong agreement with the known role of FKBP51 as an hsp90 co-chaperone of the 
glucocorticoid receptor (GR) and its subsequent regulation of GR sensitivity (Vermeer et al., 
2003;Wochnik et al., 2005). Interestingly, elevated levels of corticosterone are typically 
associated with central obesity, insulin resistance, and symptoms related to the metabolic 
syndrome as reflected in patients suffering from Cushing’s disease or patients receiving 
glucocorticoid therapy (Newell-Price et al., 2006). In the present study, we rather found 
elevated levels of corticosterone, decreased body weight, and lowered fasting blood glucose. 
Based on these findings, we deduce that the hypothalamic actions of FKBP51 on body weight 
regulation are not driven by FKBP51-dependent increases in glucocorticoids. A detailed 
characterization of the molecular events arising from manipulation of hypothalamic FKBP51 
expression is warranted. 
Previous studies have already reported tissue-specific effects of FKBP51 activity. For 
example, FKBP51 has been implicated in fine-tuning the expression of GR-regulated genes 
during adipocyte differentiation (Toneatto et al., 2013). In the brain, FKBP51 activity has 
been implicated in stress reactivity, especially at the level of the amygdala (Hartmann et al., 
2015). It is clear from such previous findings that it is essential to delineate the tissue/cell-
specific effects of FKBP51 in order to understand how FKBP51 is able to contribute to whole 
body energy homeostasis. In this regard, the current study has isolated the hypothalamic 
actions of FKBP51 from its actions in peripheral tissues or other brain centers. Although the 
hypothalamus is itself a broad brain region comprised of multiple subpopulations, each with 
distinct functions, we directed gene transfer to the hypothalamus based on the endogenous 
expression profile of FKBP51 across the VMH, PVN, and ARC (Scharf et al., 2011). Indeed 
our AAV viral-mediated overexpression of FKBP51 was very robust, and resulted in a 
pronounced body weight phenotype, partly mediated by hypophagia (see above). 
Hypophagic effects are largely mediated by the activation of POMC-containing neurons 
within the ARC (Cone et al., 2001). By contrast, NPY-containing neurons within the ARC 
are primarily responsible for hyperphagic effects. In our hypothalamic FKBP51 
overexpression experiment, FKBP51 was placed under the control of a constitutive CAG 
promoter, which drives gene expression across all cell types (Niwa et al., 1991;Okabe et al., 
1997;Pratt et al., 2000). Therefore it was important to establish the cell-specific endogenous 
(physiological) expression of FKBP51 within NPY-containing neurons and POMC-
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containing neurons. Using double in situ hybridization we sought to co-localize Fkbp5 
mRNA with either Npy or Pomc mRNA. As validation for our methodology, we found strong 
agreement between the observed and published (Allen brain atlas) Npy and Pomc expression 
profiles. Our co-expression analysis revealed that Fkbp5 is endogenously expressed in both 
NPY- and POMC-containing neuronal populations. Interestingly, our results furthermore 
indicated that there is a subpopulation of NPY neurons that do not express FKBP51. The 
functional consequence of these distinct Fkbp5-expressing subpopulations is unknown.  
Given the opposing roles of NPY- and POMC-containing neurons on body weight regulation, 
it is important to understand whether FKBP51 acts distinctly between each neuronal 
population. Indeed multiple regulatory roles and interacting partners of FKBP51 have been 
identified (Schmidt et al., 2012). In fact, it has been proposed that FKBP51 achieves pathway 
and network specificity through direct protein-protein interactions between critical nodes of 
signaling pathways and specific regulator proteins. In this manner, different functional 
outcomes may result depending on the predominant pathway regulated by FKBP51. For 
example, FKBP51 is found to be upregulated in melanoma samples where it acts as a tumor 
promoter by increasing NFB signaling (Romano et al., 2011), whereas is found to be 
downregulated in pancreatic tumor samples where it acts as a tumor suppressor by inhibiting 
AKT signaling (Pei et al., 2009). It is possible that FKBP51 likewise has distinct actions in 
NPY- and POMC-containing neurons, whose concerted actions ultimately favor a lower body 
weight phenotype. Otherwise, it is possible that endogenous FKBP51 action is stronger in 
one population over the other, in which the balance of activity promotes slower body weight 
gain. Future studies are required to understand the full extent of FKBP51 action across 
different hypothalamic cellular populations. 
In summary, we provide evidence suggesting that FKBP51 acts as a homeostatic regulator of 
body weight, in part through the regulation of food intake. First, we demonstrate that 
hypothalamic overexpression of FKBP51 reduces progression of body weight gain under 
chow and HFD conditions. Second, 51OE mice present reduced food intake compared to 
their control dietary counterparts. Finally FKBP51 is endogenously expressed within NPY- 
and POMC-containing neurons, two critical populations regulating energy expenditure and 
intake. It will be interesting to investigate whether cell-specific modulation of FKBP51 
within the hypothalamus produces similar effects to those shown here. 
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3. General Discussion 
3.1. Summary
The main objective of the current thesis was to investigate the role of FKBP51 in the 
regulation of whole body energy metabolism. In particular, we initially addressed the 
question whether FKBP51 is responsive to the dietary and/or stress condition by examining 
Fkbp5 gene expression under changing environmental conditions (Chapter 2.1 & 2.2). In 
more detailed analyses, we addressed the questions whether loss or overexpression of 
FKBP51 leads to metabolic changes, and then proceeded to characterize the molecular 
changes underlying the resulting metabolic phenotypes (Chapters 2.3, 2.4, and 2.5). Finally, 
we tested the hypothesis that FKBP51 represents a promising therapeutic target in obesity 
and T2D (Chapter 2.3). These data are the first to comprehensively examine FKBP51-
dependent metabolic regulation and the metabolic consequences following treatment with a 
selective inhibitor of FKBP51. Our findings indicate that body weight and glucose 
homeostasis are dependent on FKBP51 regulation and furthermore provide concrete evidence 
for the therapeutic potential of FKBP51 in the treatment of obesity and T2D.  
3.1.1. Fkbp5 Expression is Modulated by the Dietary Context 
In our first study (Chapter 2.1), we tested the hypothesis that FKBP51 mediates the crosstalk 
between the regulation of the stress response and energy homeostasis. This hypothesis was 
based on the notion that FKBP51 is already known to regulate the stress response (Hartmann 
et al., 2012;Touma et al., 2011) and preliminary evidence suggests it may furthermore be 
involved in metabolic and glucose homeostasis (Pei et al., 2009;Pereira et al., 2014b). In 
addition, despite mounting evidence linking chronic stress exposure to obesity and glucose 
intolerance (Bartolomucci et al., 2009;Dallman, 2010), exact targets at the interface between 
stress and energy regulation remain poorly defined. Therefore, as a preliminary study, we 
measured whether Fkbp5 gene expression is responsive to the dietary and/or stress condition 
in adult male mice, and furthermore addressed whether the dietary composition interacts with 
the stress environment to predict the expression level of Fkbp5. We focused our attention on 
the hypothalamus given its central role in both stress reactivity (Gold, 2015) and energy 
homeostasis (Saper and Lowell, 2014). Using a validated model of chronic social stress under 
both HFD-and control (chow) conditions, we found that although Fkbp5 is responsive to both 
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stress and dietary conditions, there is no interaction effect (Chapter 2.1). Although these 
findings do not establish FKBP51 as a target at the interface between stress reactivity and 
energy balance regulation per se, they highlight the fact that Fkbp5 is responsive to the adult 
dietary condition. 
In our second study (Chapter 2.2), we continued to examine gene – environment interactions 
at the Fkbp5 locus using a mouse model of maternal diet-induced obesity. We tested the 
hypothesis that in utero exposure to maternal HFD results in long-lasting alterations, which 
ultimately shape the adult phenotype. In this regard, early life dietary conditions impact adult 
gene expression of FKBP51 and thus function. This hypothesis was based on earlier findings 
that FKBP51 is a mediator of gene x early life trauma interactions to predict the risk of 
developing psychiatric disorders (Zannas and Binder, 2014). For this purpose, we examined 
the effects of prenatal exposure to maternal obesity in adult offspring on anxiety-like and 
depressive-like behaviors. In parallel we examined whether Fkbp5 gene expression is altered 
on account of in utero exposure to maternal diet-induced obesity. We report that the 
behavioral outcomes induced by prenatal exposure to maternal obesity mimic the deleterious 
effects of adult chronic stress exposure in aged male mice. This was accompanied by an 
increase in Fkbp5 gene expression within the paraventricular nucleus of the hypothalamus. 
Further studies are needed to determine a causal role of FKBP51 in mediating adverse 
behavioral outcomes resulting from prenatal exposure to maternal HFD. Nevertheless, this 
study extends the findings from our previous study, and together they demonstrate that not 
only is FKBP51 responsive to the adult dietary condition, but is likewise responsive to the in 
utero dietary condition.  
3.1.2. FKBP51 Impacts Body Weight, Glucose Homeostasis, and Metabolic 
Signaling Cascades: Possible Therapeutic Implications 
In our third study (Chapter 2.3), we asked whether the loss of FKBP51 impacts whole body 
energy metabolism, and if so how. To address this question, we characterized conventional 
FKBP51 knockout (51KO) mice under chow and HFD conditions. For this purpose, mice 
were subjected to indirect calorimetry. In additional studies body weight progression, food 
intake, glucose tolerance, and insulin tolerance were investigated. Following extensive 
metabolic phenotyping, we observed that loss of FKBP51 modestly lowers body weight 
under standard conditions and strikingly protects against HFD-induced obesity. The lower 
body weight phenotype in 51KO mice was accompanied by reduced fat pad mass and 
increased lean mass. This phenotype was very robust and was reproduced in separate 
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experiments. In order to determine the mechanistic underpinnings of the body weight 
phenotype, we assessed components of energy intake and energy expenditure. No differences 
in nutrient absorption (bioavailability) or food intake were detected between WT and 
51KOmice, indicating that the improved body weight phenotype arising from genetic ablation 
of FKBP51 does not result from modulation of energy intake. A pair-feeding experiment, in 
which WT mice were given the exact amount of HFD consumed by 51KO mice the day 
before, confirmed that complete loss of FKBP51 has no effect on energy intake. Furthermore, 
there was no genotype effect on the respiratory exchange ratio (RER), which reflects the 
relative contributions of fat and carbohydrates to oxidative metabolism, suggesting that a 
preference for fat oxidation cannot explain the reduced adiposity present in 51KO mice. 
Finally, examination of energy expenditure by indirect calorimetry revealed an increase in 
total energy expenditure (TEE) in 51KO mice. Decomposition of TEE into its resting (RMR, 
resting metabolic rate) and activity-related (AEE, activity energy expenditure) components 
revealed that the observed TEE difference was due to an increase in RMR in 51KO animals. 
We therefore conclude that the improved body weight phenotype presented in 51KO mice is 
on account of an increase in RMR. 
In order to assess whether FKBP51 acts on glucose homeostasis, a glucose tolerance test was 
performed to assess levels of circulating glucose at regular time intervals following glucose 
administration. Improved (lowered) glucose tolerance reflects either improved insulin 
secretion from the pancreas or enhanced actions of insulin to accelerate glucose uptake 
(especially in adipose tissue and skeletal muscle) and inhibit hepatic glucose production 
(Bowe et al., 2014). In our model, genetic deletion of FKBP51 lowered fasting glucose and 
improved glucose tolerance regardless of dietary (HFD or standard chow) condition. 
Examination of fasting insulin and glucose-stimulated insulin levels revealed no genotype 
effect, suggesting that the improved glucose tolerance phenotype results from improved 
insulin sensitivity rather than enhanced insulin release from the pancreas. In agreement with 
these findings, 51KO mice also showed a prolonged response to insulin examined in an 
insulin tolerance test, which assesses insulin-stimulated glucose disposal. Given the fact that 
FKBP51 is not expressed in mouse liver, the improved glucose tolerance phenotype is likely 
on account of the enhanced actions of insulin to accelerate glucose uptake. Taken together 
these data implicate FKBP51 in body weight regulation and glucose metabolism.  
In a next step, we sought to identify metabolic signaling pathways regulated by FKBP51. 
Based on the earlier finding that FKBP51 acts as a negative regulator to AKT, a central node 
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within the insulin signaling pathway (Pei et al., 2009) and the current finding that 51KO mice 
present improved glucose homeostasis, we examined the activity of the insulin signaling 
cascade. We found that genetic ablation of FKBP51 resulted in a tissue-specific increase in 
insulin signaling, selectively within skeletal muscle. To assess the functional consequence of 
FKBP51-dependent increased insulin signaling, we examined glucose uptake in the presence 
of AAV vector-mediated silencing of FKBP51 in cultured C2C12 myotubes. We report that 
AAV vector-mediated silencing of FKBP51 significantly enhanced glucose uptake in 
cultured myotubes. 
Finally, based on our earlier findings, we hypothesized that blockade of FKBP51 may 
improve obesity and/or insulin resistance. To determine whether FKBP51 inhibition 
represents a promising strategy in the treatment of obesity and/or T2D, we delivered a highly 
selective inhibitor of FKBP51 (SAFit2) to mice for 10 and 30 days. 10-day SAFit2 treatment 
significantly improved glucose tolerance, whereas 30-day SAFit2 treatment not only 
improved glucose tolerance but furthermore reduced body weight gain. At a functional level, 
SAFit2 treatment significantly augmented glucose uptake in C2C12 myotubes. These data are 
the first to demonstrate both physiologically and mechanistically the therapeutic potential of 
FKBP51 in the treatment of obesity and T2D.  
In our fourth study (Chapter 2.4), we sought to establish novel signaling pathways 
contributing to FKBP51-dependent regulation of whole body energy and glucose metabolism. 
To-date several interacting partners of FKBP51 have been reported, including several serine-
threonine kinases (Gassen et al., 2015;Pei et al., 2009;Taipale et al., 2014). Therefore using a 
candidate approach, we identified a novel regulatory role for FKBP51 in the AMPK (serine-
threonine) signaling cascade. Specifically, we identified a novel interaction between 
FKBP51, AMPK, and the direct downstream target of AMPK, TSC1-TSC2. Interestingly, the 
tuberous sclerosis complex (TSC), comprising TSC1 and TSC2, is one of the most well 
characterized regulators of mTOR. In this context, we observed an FKBP51-dependent 
regulation of the mTOR signaling cascade, in which loss of FKBP51 leads to heightened 
mTOR activity. In support of these findings, wild-type mouse embryonic fibroblasts (MEFs) 
were responsive to metformin treatment, an activator of AMPK and a known anti-diabetic 
agent. By contrast MEFs lacking FKPP51 were unresponsive to metformin, assessed by the 
phosphorylation states of proteins downstream of AMPK and mTOR. Collectively, these data 
are the first to clearly demonstrate that AMPK regulation of mTOR is dependent on FKBP51 
function. Considering the central role of AMPK in whole body energy metabolism (Kahn et 
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al., 2005), the regulatory role of FKBP51 on AMPK signaling is likely not without 
consequence. Future studies are required to determine the specific physiological context in 
which AMPK regulates mTOR signaling in a FKBP51-dependent manner.  
3.1.3. Hypothalamic FKBP51 Overexpression Paradoxically Improves the 
Metabolic Outcome in Mice 
In our fifth study (Chapter 2.5), we characterized the metabolic outcome arising specifically 
from hypothalamic overexpression of FKBP51. We hypothesized that FKBP51 hypothalamic 
overexpression would induce body weight gain and glucose intolerance based on our earlier 
findings that total loss of FKBP51 reduces body weight gain and glucose tolerance. To our 
surprise, FKBP51 overexpression within the hypothalamus resulted in lower body weight 
gain and glucose tolerance, resembling the metabolic phenotype of total 51KO mice.  
Despite the unexpected metabolic phenotype arising from targeted hypothalamic 
overexpression of FKBP51, it is nevertheless clear that FKBP51 acts within the 
hypothalamus to regulate whole body energy metabolism. Indeed the hypothalamus is a 
crucial area within the central nervous system regulating feeding behavior, body weight, 
energy metabolism, and glucose metabolism, and therefore FKBP51 has the potential to 
modulate multiple functional outcomes. However, the questions of how and where FKBP51 
acts within the hypothalamus remain elusive. Given the cellular and functional heterogeneity 
of the hypothalamus, this concern needs to be addressed. We overexpressed FKBP51 within 
the hypothalamus across the arcuate nucleus (ARC), paraventricular nucleus (PVN), 
ventromedial hypothalamic nucleus (VMH), and dorsomedial hypothalamic nucleus (DMH). 
We initially aimed to broadly target the hypothalamus because we had no a priori knowledge 
as to whether or not hypothalamic overexpression would have any effect on the metabolic 
outcome whatsoever. Furthermore, based on the known expression profile of FKBP5 across 
the ARC, PVN, and VMH, we wanted to target each of these nuclei. In mice, the DMH does 
not express FKBP51, however FKBP5 was nevertheless found overexpressed in our study. 
From this experiment, we can conclude that FKBP51 acts broadly within the hypothalamus to 
decrease body weight, partly through its effect on food intake.  
Within the hypothalamus, there are multiple neuronal types that act in concert to sense, 
integrate, and respond to hormonal and nutritional signals (Refer to  General Introduction). 
Such concerted actions often require reciprocal actions across distinct neuronal populations. 
The integrated response of the summated actions dictates the phenotypic expression. For 
example, within the ARC two populations of neurons exist which have opposing effects on 
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food intake (Refer to  General Introduction). Activation of POMC-expressing neurons favors 
reduced food intake, whereas activation of NPY-expressing neurons favors increased food 
intake. The level of activation of each neuronal population governs feeding behavior. 
Therefore in the context of FKBP51, it was important to determine the cell type-specific 
expression profile of FKBP51. Suppose FKBP51 is exclusively expressed in NPY-containing 
neurons, but in the current study we overexpressed FKBP51 across all cell types using a 
strong synthetic promoter (CAG) to drive high levels of gene expression. Our findings may 
be confounded by poor spatial and/or cell type-specific resolution. Therefore, as an initial 
first step, we established whether FKBP5 is expressed in NPY-containing neurons, POMC-
containing neurons or both using double in situ hybridization. We are the first to identify that 
FKBP5 is expressed in both neuronal populations within the ARC. Future studies should 
target discrete neuronal populations within discrete hypothalamic nuclei in order to resolve 
the role of FKBP51 in each subpopulation. 
Based on our past findings (Chapter 2.3) and current findings (Chapter 2.5), we conclude that 
the metabolic phenotype arising from total loss of FKBP51 is not mediated centrally through 
the hypothalamus, and we postulate that FKBP51 action in the periphery plays a more 
prominent role in whole body energy metabolism. Indeed the larger energy balance system 
encompasses multiple tissues, including many peripheral tissues presenting high levels of 
Fkbp5 expression. For example FKBP5 shows the highest mRNA expression profile in 
human skeletal muscle, adipose tissue, and immune cells (Su et al., 2004). Interestingly, 
adipose-specific functions of FKBP51 in adipogenesis have already been reported (Toneatto 
et al., 2013). Our findings that FKBP51 selectively regulates the insulin signaling cascade 
within skeletal muscle, furthermore strengthens the notion that FKBP51 action in peripheral 
tissues is an important regulatory component for whole body energy and glucose 
homeostasis. Conditional transgenic mouse models with high spatial and temporal resolution 
are required to fully address the question as to where FKBP51 acts to regulate whole body 
energy and glucose homeostasis. At a physiological level, it is likely that the concerted action 
of FKBP51 across multiple tissues is required. 
3.2. Significance to the Research Field 
3.2.1. FKBP51: A Genetic Risk Factor in Metabolic Diseases 
The current thesis provides a strong framework for understanding the relationship between 
FKBP51 and whole body energy homeostasis. We demonstrate that the dietary environment 
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alters FKBP51 expression. In turn, fluctuations in FKBP51 expression lead to diverging 
metabolic phenotypes. For example, based on our findings that complete loss of FKBP51 
improves the metabolic phenotype of mice, one could speculate that physiological differences 
in FKBP51 may contribute to an individual’s susceptibility to develop obesity or T2D. This is 
in line with an earlier study which reported that FKBP5 gene expression in subcutaneous 
adipose tissue positively correlates with HOMA-IR (an index of insulin resistance (Pereira et 
al., 2014b). In parallel, this same study used data from genome-wide association studies to 
demonstrate that a number of genetic variants within the FKBP5 gene loci associate with 
traits of T2D.  
Environmental factors are just as important as genetic factors in predicting susceptibility to 
obesity and/or T2D. In other words, individuals become obese when they are genetically 
susceptible to the obesogenic environment of Western society. In the context of the genetic 
risk factor FKBP51, 51KO mice are only moderately leaner than WT mice under standard 
diet conditions. It is not until they are challenged with a HFD that a diverging metabolic 
phenotype manifests between 51KO and WT mice. Along these same lines, obesity has only 
recently reached epidemic proportions, suggesting that genetic susceptibility and/or resilience 
to obesity is only realized when challenged by environmental factors (i.e. Western diets). 
This highlights the complexity of body weight regulation and glucose homeostasis. Many 
environmental conditions (besides HFD) and additional genetic factors (besides FKBP51) are 
indeed involved in predicting disease (obesity and T2D) vulnerability. Nevertheless, the in-
depth metabolic characterization of FKBP51 knockout mice identifies FKBP51 as a novel 
genetic risk factor for metabolic diseases and also extends our current understanding of the 
detailed genetic profile relevant to metabolic regulation (Figure 3.2.1).  
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Figure 3.2.1 The metabolic phenotype arising from genetic ablation of FKBP51 
Metabolic studies were conducted on 51KO and WT mice. 51KO mice presented decreased fat pad 
mass and increased lean mass under both HFD and control conditions, and were furthermore 
protected against HFD-induced weight gain. To examine the mechanism underlying the body 
weight phenotype, parameters comprising energy storage, energy intake, and energy expenditure 
were monitored. Loss of FKBP51 had no effect on home cage activity level, body temperature, 
substrate utilization, digestive efficiency (nutrient absorption), or feeding. However increased 
energy expenditure (heat production) may explain the lower body weight of 51KO mice compared 
to WT mice. Finally investigation into parameters of glucose homeostasis revealed that loss of 
FKBP51 decreased fasting glucose, lowered glucose tolerance, and prolonged the response to 
insulin during an ITT. 
 
3.2.2. FKBP51: Novel and Established Molecular Mechanisms Governing Energy 
and Glucose Metabolism 
Novel Molecular Mechanisms 
Identification of underlying mechanisms by which newly identified genetic factors function 
to modulate metabolic regulation strengthens the existing, known molecular framework. In 
our case we identify FKBP51 as an important regulator of insulin signaling in the context of 
glucose homeostasis and furthermore as a novel regulator of AMPK-mTOR signaling 
pathways. The finding that FKBP51 regulates glucose homeostasis by modulating the insulin 
signaling cascade at the AKT locus identifies a previously unrecognized consequence of 
FKBP51-dependent AKT regulation. In general, the insulin signaling cascade stimulates 
glucose transport in skeletal muscle and adipose tissue. More precisely, it has been shown 
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that Akt is both necessary and sufficient for insulin-stimulated glucose transport (Sakamoto 
and Holman, 2008). Of the 3 AKT isoforms, AKT2 shows the highest expression in insulin 
sensitive tissues and likewise shows the strongest association to glucose uptake (Vasudevan 
and Garraway, 2010). Importantly, AKT2 knockout mice present glucose intolerance and 
insulin resistance owing to impaired insulin-stimulated glucose uptake in skeletal muscle and 
adipose tissue (Cho et al., 2001). This is in agreement with our findings in which 51KO mice 
present improved glucose and insulin tolerance owing to enhanced AKT activation (reduced 
inhibition by PHLPP) and increased glucose uptake in skeletal muscle. Therefore, while AKT 
is already well recognized to play a pivotal role in glucose transport, the regulation of AKT, 
and the identity of specific modulator proteins, is yet to be completely understood. In this 
sense, the interaction between AKT and FKBP51 resulting in functional changes at the level 
of glucose transport is highly relevant, especially concerning AKT regulation of glucose 
transport specifically within skeletal muscle.  
Using a candidate approach, we furthermore identified a novel interaction between AMPK, 
TSC1/2, and FKBP51. AMPK is a conserved serine-threonine kinase which functions as a 
cellular and whole body energy sensor (Towler and Hardie, 2007). Under low energy 
conditions, activation of AMPK restores intracellular ATP levels by enhancing catabolic 
metabolism while inhibiting anabolic metabolism (Section 1.6.3.). Although well-recognized 
for its regulation of whole body energy metabolism, its own regulation is incompletely 
understood. Therefore the novel interaction between FKBP51, AMPK, and TSC1/2 is highly 
significant. Importantly, this novel interaction is functionally linked to mTOR activation, in 
which we demonstrate that AMPK inhibition of mTOR depends on FKBP51. Interestingly, 
our findings, reported here, compliment an earlier study which mapped protein-protein 
interactions using a proteomic approach (Taipale et al., 2014). In this earlier study, FKBP51 
was identified as an interacting partner of LKB1, an upstream serine-threonine kinase that 
directly phosphorylates and activates AMPK (Shackelford and Shaw, 2009). Thus our study 
contributes important novel information to the growing research on AMPK regulation, 
suggesting that FKBP51 acts to direct AMPK action towards select targets and to furthermore 
organize the AMPK heterocomplex, including both upstream regulators (LKB1) and 
downstream effectors (TSC1/2). 
Insulin signaling and AMPK-mTOR signaling are not mutually exclusive. Rather their 
concerted actions are integral to the larger interconnected metabolic regulatory network, 
which functions to maintain energy and glucose homeostasis (see Section 1.6.3). We and 
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others (Pei et al., 2009) have demonstrated that FKBP51 interacts with several proteins along 
the integrated pathway to ultimately regulate the activity of various nodes. Interestingly, 
although FKBP51 binds to distinct binding partners along this metabolic regulatory network, 
its overall action appears somewhat redundant. For example, in complex with AMPK and 
TSC1/2, FKBP51 increases the inhibition efficiency of AMPK-TSC1/2 on downstream 
mTOR signaling. Similarly, in complex with AKT and PHLPP, FKBP51 decreases the 
activation efficiency of AKT, which subsequently also favors mTOR inactivation (Figure 
3.2.2). Taken together, these data suggest that FKBP51 is an important regulator of this 
integrated metabolic regulatory network, acting at multiple levels to regulate redundant or 
related homeostatic functions.  
A major focus of research related to signal transduction pathways is to understand how 
protein kinases are able to achieve functional specificity in order to regulate multiple cellular 
functions in response to different environmental stimuli. Protein-protein interactions are 
inevitably very important determinants for recruiting and concentrating specific signaling 
molecules to discrete regulatory proteins. Targeting such protein-protein interactions that 
govern the specificity between binding partners improves our overall understanding of how 
signaling cascades achieve specificity. Importantly, in order to achieve functional specificity 
in response to specific environmental contexts, it is important that molecular targets are able 
to sense and furthermore respond to the environment. AMPK, mTOR, and FKBP51 all have 
the capacity to sense the environment. In particular, AMPK responds to low energy 
conditions (Hardie, 2015), mTOR responds to nutritional status (i.e. amino acids) 
(Wullschleger et al., 2006), and FKBP51 responds to both stress (Guidotti et al., 2013;Scharf 
et al., 2011) and dietary (Balsevich et al., 2014) conditions. Therefore, based on previous 
findings and the current work, we believe that FKBP51 may function as a scaffolding protein 
coordinating the signal transduction between AMPK, AKT, and mTOR by attracting various 
proteins required for the correct signaling cascade in response to the environmental stimuli. 
Established Molecular Mechanisms 
Besides the novel molecular mechanisms involving FKBP51 characterized in the current 
thesis, the well-established role of FKBP51 in the stress response and glucocorticoid 
signaling cannot be neglected. As a co-chaperone to the hsp90, FKBP51 decreases GR 
ligand-binding sensitivity and nuclear translocation efficiency (Section 1.8.) (Denny et al., 
2000;Scammell et al., 2001;Westberry et al., 2006;Wochnik et al., 2005). Importantly, 
through a short-loop negative feedback system, fkbp5 expression is itself induced by GR 
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activation (Vermeer et al., 2003). This has important implications because of the association 
between high levels of FBP51 expression and adverse metabolic outcomes (current thesis; 
(Pereira et al., 2014b)). Therefore, does chronic stress predispose individuals to body weight 
gain, partly through the upregulation of FKBP51? In support of this, 51KO mice are less 
susceptible to stress-induced body weight gain examined in the chronic social defeat stress 
paradigm (Hartmann et al., 2012). Indeed, chronic stress is a known risk factor for metabolic 
disorders, namely obesity and T2D (Marcovecchio and Chiarelli, 2012). Yet there is a lack of 
known molecular targets governing this relationship. Further investigation is required to 
systematically characterize whether FKBP51 is involved in stress-induced body weight gain. 
In addition, it is important to delineate how chronic stress exposure governs the diverse roles 
of FKBP51 and to identify whether stress exposure favors specific protein-protein 
interactions involving FKBP51 over other interactions to ultimately dictate functional 
specificity.  
Collective FKBP51-Mediated Mechanisms 
In summary, the current dataset strongly suggests that FKBP51 may provide functional 
specificity to signaling cascades through multiple protein-protein interactions. Not only is 
FKBP51 a multi-domain protein whose structure is suitable for protein-protein interactions, 
but also FKBP51 is highly responsive to environmental cues, allowing it to mount a 
particular response to various stimuli. Our data indicate that reduced FKBP51 expression is 
associated with favorable metabolic outcomes. However, this is founded in the context of an 
obesogenic context. Given the pleiotropic functions of FKBP51, it is likely that FKBP51 
expression and function may have both beneficial and disadvantageous outcomes depending 
on the context.  
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Figure 3.2.2 Working model of FKBP51 action on the metabolic regulatory network 
Working model showing how the larger metabolic regulatory network may operate under 
conditions where FKBP51 is present (i.e. WT conditions) or lost (i.e. 51KO conditions or 
pharmacological blockade). The efficacy of signaling cascades depend on protein-protein 
interactions between critical signaling nodes and their respective regulators. Under WT conditions, 
FKBP51 acts as a scaffolding protein between AKT and PHLPP thereby down-regulating AKT 
signaling. Likewise, FKBP51 is in complex with AMPK, TSC1 and TSC2 thereby down-regulating 
mTOR signaling. Functionally, the resulting specific pattern of network connectivity favors 
reduced glucose uptake in the presence of FKBP51. Under 51KO conditions, loss of FKBP51 
results in reduced inhibition of AKT and subsequently increased AKT downstream signaling. 
Likewise, AMPK-dependent inhibition of mTOR signaling is reduced under 51KO conditions. 
Functionally, loss of FKBP51 results in a specific pattern of network connectivity that favors 
increased glucose uptake. 
3.2.3. FKBP51: Implications for the Treatment of Obesity and Type 2 Diabetes 
Effective pharmacological treatment strategies for obesity and related complications remain 
elusive. Importantly, most currently available treatment options are able to address, at best, 
one disease mechanism (Grundy, 2006). For example, for the treatment of T2D, treatment 
often includes combination drug therapy in which separate agents are used to treat insulin 
deficiency and insulin resistance. Similarly, despite the high comorbidity between obesity 
and T2D, first-line pharmacological intervention strategies are not able to overcome both 
disease states. Therefore, research is currently exploring possible novel candidates that are 
able to target multiple risk factors more effectively. This requires the discovery of new, 
multifunctional molecules that act on numerous key pathways, whose concerted action 
governs energy balance and glucose homeostasis.  
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We identified FKBP51 as a novel genetic factor involved in metabolic regulation. 
Importantly, our mechanistic investigation demonstrated that FKBP51 indeed functions as a 
multifunctional molecule able to interact with multiple proteins at critical nodes along key 
pathways involved in energy balance and glucose homeostasis. To translate the current 
findings into a therapeutic context, we also established whether pharmacological blockade 
affects body weight and/or glucose homeostasis. We report that highly selective blockade of 
FKBP51 (using SAFit2) indeed has therapeutic promise. In fact, a 30-day treatment schedule 
reduced both body weight gain and glucose tolerance. Our comprehensive data set directly 
implicates FKBP51 in metabolic regulation and provides physiological and mechanistic 
evidence for the therapeutic potential of FKBP51 in the treatment of both obesity and T2D.  
3.3. Limitations and Future Directions
We present compelling data that identify FKBP51 as a novel molecule involved in energy 
balance and glucose homeostasis. This opens a new avenue of research, which has the 
potential to advance current medical practices. Despite our in-depth characterization of 
FKBP51 function in the context of whole body metabolic regulation, there remain 
outstanding research questions. Two of the most pressing issues regarding the metabolic 
functions of FKBP51 are the following: 
a. Which tissues mediate the metabolic actions of FKBP51? 
b. How does FKBP51 respond to changing environmental contexts in order to 
regulate energy balance and glucose homeostasis? 
3.3.1. Tissue-Specificity of FKBP51 
In order to explore the metabolic function of FKBP51, we characterized the metabolic 
phenotype in total FKBP51 knockout mice. Although conventional 51KO mice provided a 
means to establish whether FKBP51 is involved in metabolic regulation or not, there are 
many shortcomings associated with any conventional knockout mouse line. For example, 
there is inevitably a lack of spatial and temporal control of gene expression. Furthermore the 
possibility exists that compensatory changes during development by other molecules may 
occur in the absence of the deleted gene. Therefore temporal and spatial transgenic animal 
models are preferred. In the specific case of FKBP51, tissue specificity is certainly an 
important consideration. For example, FKBP5 is highly expressed across multiple tissues (Su 
et al., 2004), many of which are integral to whole body energy balance and glucose 
homeostasis. The contribution of individual tissue types, or specific cell types, must be 
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addressed in the future. Our data already highlight the tissue- specific effects of FKBP51, 
whereby FKBP51-dependent regulation of the insulin signaling cascade, and consequently 
glucose transport, is restricted to skeletal muscle. Likewise, across the whole hypothalamus, 
overexpression of FKBP51 resulted in reduced body weight gain, accompanied by a 
reduction in food intake. Previous studies have also highlighted tissue-specific actions of 
FKBP51, most notably in adipose tissue where it is involved in the regulation of adipogenesis 
(Toneatto et al., 2013). In addition, Pereira et al. also showed tissue-specific effects of 
FKBP51 whereby the positive association between FKBP5 mRNA and HOMA-IR was 
restricted to subcutaneous adipose tissue and was not significant in the other examined 
adipose depots (Pereira et al., 2014b). Although the current work advances our understanding 
of the tissue-specific effects of FKBP51, (summarized in Figure 3.3.1), systematic 
characterization of the tissue-specific contributions of FKBP51 is still lacking. 
 
Figure 3.3.1 Tissue-specific FKBP51 regulation of whole body energy and glucose 
homeostasis 
Across the whole hypothalamus, FKBP51 acts to decrease food intake (Chapter 2.5.). In skeletal 
muscle, FKBP51 acts to increase insulin sensitivity and glucose uptake (Chapter 2.3.). We found 
no effect of FKBP51 on insulin secretion from the pancreas, while FKBP51 is not expressed in 
mouse hepatocytes (Chapter 2.3.). Finally a previous study implicates FKBP51 in the regulation of 
adipogenesis in adipose tissue (Toneatto et al., 2013). Collectively, FKBP51 is able to act at 
multiple levels in order to modulate metabolic outcomes. 
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3.3.2. Responsiveness of FKBP51 to Environmental Cues 
Although FKBP51 has been studied in the context of stress reactivity and as a stress-induced 
gene (Guidotti et al., 2013;Pereira et al., 2014b;Scharf et al., 2011;Vermeer et al., 2003), little 
research has been devoted to understanding how FKBP51 responds to additional 
environmental cues. Here we only begin to dissect how energy status and nutrient conditions 
influence FKBP51 expression and function. For example, HFD exposure increases 
hypothalamic expression of Fkbp5. Moreover, only under HFD conditions, does loss of 
FKBP51 produce a strong body weight phenotype. Nevertheless, it is important to understand 
the tissue-specific responsivity of Fkbp5 as well as to understand how the nutrient 
environment affects FKBP51 function. For example, in conditions of high or low energy 
status, does FKBP51 preferentially bind to specific binding partners? This will shed light into 
the mechanisms underlying the HFD-resistant body weight phenotype presented in 51KO 
mice. Finally, it is highly relevant to understand the interaction between FKBP51, stress 
exposure, and dietary conditions. Specifically, could FKBP51 act at the interface between 
stress-related psychiatric disorders and metabolic disorders? Indeed there is a high 
comorbidity between psychiatric and metabolic disorders despite a lack of clear molecular 
targets responsible for this relationship. Although our preliminary study (Chapter 2.1) did not 
reveal that FKBP51 governs gene x environment interactions mediating the shared biology of 
psychiatric and metabolic disorders, it was a targeted, observational study. Based on the 
responsiveness of FKBP5 to the environment and its association to both psychiatric and 
metabolic diseases, examination into the role of FKBP51 on stress-dependent metabolic 
outcomes is warranted. 
3.4. Closing remarks 
We provide new insights into the regulation of energy balance and glucose homeostasis, 
which opens a new avenue of research, not yet widespread in literature. Future studies will be 
able to build on these findings, to provide an even clearer picture in order to understand the 
exact mechanisms underlying the FKBP51-dependent mechanisms mediating the metabolic 
effects on body weight regulation and glucose homeostasis. 
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